

CURRICULUM VITAE

(updated December 2019)

Name: Andrew Blauvelt, M.D., M.B.A.

Date and Place of Birth: February 12, 1962, Ypsilanti, MI

Work Address:

9495 SW Locust Street

Suite G

Portland, OR 97223

Phone: 503-245-1525

Fax: 503-245-0315

E-mail: ablauvelt@oregonmedicalresearch.com

Education/Training:

1980-1984 B.S., Electrical Engineering, Purdue University, West Lafayette, IN
1984-1988 M.D., Michigan State University, East Lansing, MI
1988-1989 Intern, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI
1989-1992 Dermatology Resident, Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL
1992-1995 Postdoctoral Fellow, Dermatology Branch (in the laboratory of Stephen I. Katz, M.D., Ph.D.), National Cancer Institute, Bethesda, MD
1995-1996 Postdoctoral Fellow, Molecular Virology Section (in the laboratory of Kuan-Teh Jeang, M.D., Ph.D.), Laboratory of Molecular Microbiology, National Institute for Allergy and Infectious Diseases, Bethesda, MD
2010-2013 M.B.A. in Healthcare Management, Oregon Health & Science University/Portland State University, Portland, OR

Employment:

1996-2003 Investigator (Tenure-Track) and Head, Viral Pathogenesis Section, Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
2003-2004 Senior Investigator (Tenured) and Head, Viral Pathogenesis Section, Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
1999-2001 Adjunct Assistant Professor, Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD
2001-2004 Adjunct Associate Professor, Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD
2004-2011 Adjunct Professor, Department of Dermatology, Uniformed Services University, Bethesda, MD
2004-2011 Professor, Department of Dermatology, Oregon Health & Science University, Portland, OR
2004-2011 Professor, Department of Molecular Microbiology and Immunology,

	Oregon Health & Science University, Portland, OR
2004-2011	Chief, Dermatology Service, Veterans Affairs Medical Center, Portland, OR
2011-present	Affiliate Professor, Department of Dermatology, Oregon Health & Science University, Portland, OR
2011-present	Investigator, Oregon Medical Research Center, Portland, OR
2011-2014	Private practice, Klein Dermatology & Associates, Portland, OR
2013-present	President and Owner, Oregon Medical Research Center, Portland, OR (http://www.oregonmedicalresearch.com/)
2014-2015	Private practice, Dermatology Associates, Portland, OR
2015-present	Private practice, Baker Allergy, Asthma & Dermatology, Portland, OR

Uniformed Service:

1992-1993	U.S. Public Health Service (Lieutenant)
1993-1997	U.S. Public Health Service (Lieutenant Commander)
1997-2004	U.S. Public Health Service (Commander)

Certification/Licensure:

1989	Diplomate, National Board of Medical Examiners
1992	Certification in Dermatology, American Board of Dermatology
1993	Certification in Clinical and Laboratory Dermatological Immunology, American Board of Dermatology
1991-2004	Medical License, State of Maryland
2001, 2011	Re-certification in Dermatology, American Board of Dermatology
2004-present	Medical License, State of Oregon

Professional Societies and Activities:

American Academy of Dermatology (1990-present)

- Sexually Transmitted Diseases Task Force (1994-1995)
- Invited Speaker, Stephen Rothman Club (1998, 2003)
- Study Group on Medical Dermatology (1999)
- Psoriasis Task Force/Expert Resource Group (2000-2004)
- HIV/STD Task Force/Expert Resource Group (2000-2004)
- Invited participant, Forum for Future Leaders in Dermatology (2002)
- Invited chairperson, Residents & Fellows Symposium, Annual Meeting (2002-2005)
- Invited participant, Psoriasis Therapies Educational Summit (2002)
- Invited member, Research Committee (2007-2009)
- Invited member, Congressional Policy Committee (2009-2010)
- Invited member, Camp Discovery Committee (2011-2013)
- Invited member, Atopic Dermatitis Education Task Force (2019-present)

Society for Investigative Dermatology (1994-present)

- Investigator/Fellow Dinner Program (1997-2007)
- Education for Students Program (1999-2007)
- Committee on Albert M. Kligman Fellowships (2000-2004)
- Committee on Clinical Scholars Program (2001-2004)
- Invited chairperson, minisymposia at annual meetings (2001, 2003-2004, 2007-2008,

2010)

- Invited speaker, retreat to recruit physician-scientists (2001, 2003)
- Chairperson, Committee on Resident and Fellow Programs (2002-2005)
- Invited abstract reviewer for annual meetings (2003-2005, 2010)
- Invited Co-Chair, Psoriasis Research Symposium, 2017

Washington D.C. Dermatological Society (1996-2004)

American Association for the Advancement of Science (1996-2010)

American Society for Microbiology (1997-2006)

American Association of Immunologists (1997-2010)

Dermatology Foundation (1998-2011)

- Invited member, Medical and Scientific Committee (2004-2007)
- Invited chairperson, Medical and Scientific Committee (2007)
- Invited Vice Chairman for the State of Oregon (2006-2007)
- Leader's Society (2006-2011)

National Psoriasis Foundation (1998-present)

- Professional member (1998-present)
- Invited member, Medical Advisory Board (2001-2004, 2007-2013)
- Invited member, Board of Trustees Research Committee (2004)
- Selected Honorary Medical Chair, Walk to Cure Psoriasis in Portland (2007-2010)
- Invited member, Scientific Advisory Board (2009-2014)
- Member, President's Council (2009-present)
- Invited member, Scientific Advisory Committee (2010-2011, 2016-present)
- Invited member, Translational Grant Review Committee (2011)
- Invited member, Emeritus Medical Board (2015-present)

American Society for Clinical Investigation (2004-2012)

Oregon Dermatology Society (2004-present)

- Board of Directors (2010-2013)
- President-elect (2010-2011)
- President (2011-2012)
- Immediate Past President (2012-2013)

Oregon Medical Association (2004-present)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (2006-present)

American Dermatological Association (2007-present)

- Member, Meeting Site Committee (2008-2011)

Invited Scientific Program Co-Chair, "The Biologic Basis of Psoriasis," 57th Annual Montagna Symposium on the Biology of Skin (2008)

Pacific Dermatologic Association (2008-2009)

- Invited Scientific Program Chair for the annual meeting (2009)

Clinical Immunology Society, invited session chair at annual meeting (2010)

Association of Professors of Dermatology (2010-2011)

Invited Member, Executive Committee, Dermatology Comparative Effectiveness Research Network (2010-2015)

Invited Councilor, International Psoriasis Council (2011-present)

- Chair, Biosimilars Working Group (2013-2016)
- Member, Patient Care Committee (2017-present)
- Member, Moderate Psoriasis Committee (2017-present)

Member, Pediatric Dermatology Research Alliance Guidance Document for Industry Committee (2016-2017)
Member, European Academy of Dermatology and Venereology (2017-present)
Invited Councilor, International Eczema Council (2019-present)

Committees and Local Activities:

Volunteer dermatologist, Whitman-Walker Clinic, Washington, D.C. (1997-1999)
Invited member, Search Committee for Dermatology Branch Clinical Researcher (1998)
Invited ad hoc reviewer, NIH extramural (NIAID and NIAMS) grants in immunology, HIV/AIDS, and dermatology (1998-2005)
Member, NCI Institutional Review Board (1999-2001)
Invited lecturer, International Society for Infectious Diseases International HIV/AIDS Training Program (1999-2002)
Member, NIH AIDS Malignancy Working Group (1999)
Interviewer of prospective medical students, Uniformed Services University of the Health Sciences (1999-2003)
Member, Trans-NIH Microbicide Working Group (1999-2004)
Member, NIH Pharmacy and Therapeutics Committee (2000-2004)
Invited abstract judge, NIH Fellows Award for Research Excellence (2001-2003)
Member, NCI HIV and Cancer Virology Faculty (2001-2004)
Member, NCI Immunology Faculty (2001-2004)
Member, NCI Vascular Biology Faculty (2001-2004)
Invited member, Search Committee for Dermatology Branch Staff Clinician (2002)
Invited member, Research Evaluation and Decision Panel for the AIDS and Cancer Specimen Resource (2004)
Member, OHSU Cancer Institute (2004-2009)
Member, Medical Staff Council, Portland VA Medical Center (2004-2011)
Faculty Coordinator, OHSU Department of Dermatology Basic Science Journal Club (2004-2011)
Faculty Coordinator, OHSU Department of Dermatology Resident Research Rotation (2004-2011)
Member, OHSU Department of Dermatology Executive Committee (2004-2011)
Founder and Director, OHSU Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA) (2006-2011)
Invited ad hoc member, OHSU thesis defense committee for Ph.D. candidate, Cortny Huddleston (2006)
Invited member, Oregon Health Plan Subcommittee on Targeted Immune Modulators (2007)
Invited participant, Roundtable discussion on psoriasis, psoriatic arthritis, and rheumatoid arthritis sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (2007)
Invited member, OHSU qualifying examination committee for Ph.D. candidate, Kalmia Buels (2007)
Volunteer, Oregon Museum of Science and Industry Body Worlds exhibit (2007)
Member, OHSU Department of Dermatology Storrs Lectureship Committee (2009-2012)
Faculty advisor to OHSU medical students: Brian Truong, Courtney Bell, Janelle Minter (2009-2011)

Volunteer mentor, OHSU Science Class Program for high school students (2010)
Volunteer, OHSU head & neck cancer screening (2010)
Invited ad hoc reviewer, Oregon Clinical and Translational Research Institute pilot grant Program (2010)
Invited member, Aarhus University thesis defense committee for Ph.D. candidate, Claus Johansen (2010)
Director, OHSU Department of Dermatology Kingery Library Committee (2010-2011)
Faculty Advisor, Dermatology Interest Group for OHSU medical students (2010-2011)
Faculty advisor to OHSU dermatology training grant pre-doctoral student: Joshua Walker (2010-2011)
Reviewer for Pharmacy Committee Recommendations and Policy, Regence Blue Cross/Blue Shield, Portland, OR (2010-present)
Volunteer dermatologist, Wallace Medical Concern, Portland, OR (2013-2017)
Faculty advisor to OHSU pre-doctoral student: Sarah Siegel (2016-present)

Journal Activities:

Editorial Board, *Journal of the American Academy of Dermatology* (1998-2007)
Feature Editor, "Dermatology Grand Rounds at the NIH," *Journal of the American Academy of Dermatology* (2000-2004)
Assistant Editor, *Journal of the American Academy of Dermatology* (2004)
Associate Editor (Science), *Journal of the American Academy of Dermatology* (2004-2007)
International Advisory Board, *Journal of Dermatology* (2000-present)
Associate Editor, *Journal of Investigative Dermatology* (2002-2009)
Editorial Board, *Journal of Dermatological Science* (2003-present)
Section Head, "Psoriasis & Other Inflammatory Diseases" and Dermatology Advisory Board, Faculty of 1000 Medicine (2004-2011)
Editorial Board, *Psoriasis Forum* (2006-present)
Editorial Board, *Annals of Dermatology* (2009-present)
Section Editor (Immunology/Infection), *Journal of Investigative Dermatology* (2009-2011)
Board of Consulting Editors, *Journal of Clinical Investigation* (2010-2012)
Editorial Board, *Journal of Clinical and Experimental Dermatology* (2010-2011)
Associate Editor, Translational Research, *British Journal of Dermatology* (2019-present)
Reviewer: *New England Journal of Medicine*, *The Lancet*, *Science*, *Journal of Experimental Medicine*, *Proceedings of the National Academy of Sciences*, *Journal of Clinical Investigation*, *Journal of Biological Chemistry*, *Journal of Immunology*, *Journal of Leukocyte Biology*, *Immunology Letters*, *Journal of Immunological Methods*, *Journal of Immunotherapy*, *Clinical Immunology*, *International Immunology*, *Expert Review of Clinical Immunology*, *The Lancet Infectious Diseases*, *Journal of Virology*, *Virology*, *AIDS*, *AIDS Research and Human Retroviruses*, *Journal of the Acquired Immune Deficiency Syndrome*, *Antiviral Therapy*, *Journal of Infectious Diseases*, *Clinical Infectious Diseases*, *Clinical and Microbiological Reviews*, *Journal of the National Cancer Institute*, *Cancer Research*, *Blood*, *Current Molecular Medicine*, *Expert Reviews in Molecular Medicine*, *Journal of Cellular Physiology*, *F100 Biology Reports*, *Clinical Science*, *Hepatology*, *American Journal of Pathology*, *Arthritis and Rheumatism*, *Annals of Epidemiology*, *Journal of Investigative Dermatology*, *Archives of Dermatology*, *Journal of the American Academy of Dermatology*, *British Journal of Dermatology*, *Journal of Dermatological*

Science, Journal of Dermatology, Experimental Dermatology, Journal of the European Academy of Dermatology and Venereology, Annals of Dermatology, Dermatologic Surgery, American Journal of Contact Dermatitis, Psoriasis Forum, Medical Hypotheses, The Medical Letter, British Journal of Ophthalmology

Clinical Study Activities:

1996-2003	Principal Investigator for NIH intramural study #76-C-0293, "Induction of suction blisters in patients with urticaria, blistering diseases, inflammatory dermatoses and neoplastic disorders, and in normal volunteers"
1996-1999	Principal Investigator for NIH intramural study #93-C-0050, "Induction of suction blisters in HIV-infected patients"
1998-2004	Principal Investigator for NIH intramural study #96-C-0097, "The acquisition of blood and skin samples from patient volunteers to support research activities on dermatologic diseases"
1999-2000	Principal Investigator for NIH intramural study #99-C-0027, "Randomized double-blind placebo-controlled trial using recombinant human interleukin-10 for moderate-to-severe psoriasis"
2000-2002	Principal Investigator for NIH intramural study #00-C-0211, "A pilot open-label single-dose study using intravenous micellar paclitaxel for patients with severe psoriasis"
2001	Principal Investigator for NIH intramural study #02-C-0246, "Validation of a survey instrument for future psoriasis studies"
2004	Principal Investigator for NIH intramural study #04-C-0036, "Induction of suction blisters in healthy volunteers"
2004-2005	Co-investigator for OHSU study #578, "Efalizumab for moderate to severe atopic dermatitis - a phase I pilot study in adults"
2005-2009	Principal Investigator for OHSU study #1630, "Expression of p19, p40, and p35 in skin"
2006-2011	Principal Investigator for OHSU study #2364, "A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis (PHOENIX 2)"
2006-2011	Principal Investigator for OHSU study #2568, "Role of IL-23 and other cytokines in psoriasis and atopic dermatitis pathogenesis"
2006-2010	Principal Investigator for OHSU study #2938, "Induction of suction blisters in healthy volunteers"
2006-2007	Co-investigator for OHSU study #2570, "A phase 3, randomized, double-blind study to evaluate the efficacy and safety of BID application of tacrolimus cream-B 0.1% versus cream-B vehicle in the treatment of psoriasis"
2008-2010	Principal Investigator for OHSU study #3912, "A multicenter, open-label study to assess the efficacy and safety of infliximab (Remicade®) therapy in patients with plaque psoriasis who had an inadequate response to etanercept (Enbrel®) (PSUNRISE)"

2008-2009 Principal Investigator for OHSU study #4255, "Investigating the IL-23/IL-17 inflammatory pathway in psoriasis patients receiving Remicade therapy"

2008-2009 Principal Investigator for OHSU study #4128, "A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis"

2008-2011 Principal Investigator for OHSU study #4570, "A phase 3, multicenter, open-label continuation study for moderate to severe chronic plaque psoriasis subjects who completed a preceding psoriasis study with ABT-874"

2008-2009 Principal Investigator for OHSU study #4499, "Phase 2A randomized, double-blind, vehicle-controlled, intra-individual comparison trial assessing safety, toleration, pharmacokinetics and pilot efficacy of 4 weeks treatment with CP-690,550 in chronic plaque psoriasis"

2008-2010 Principal Investigator for OHSU study #4875, "LY2439821 (anti-IL-17 humanized antibody) multiple-dose safety and tolerability study in subjects with psoriasis vulgaris"

2008-2011 Principal Investigator for OHSU study #4760, "Clinical database for patients with psoriasis"

2008-2011 Principal Investigator for OHSU study #4953, "A randomised, placebo-controlled, single- and multiple-dose, dose escalation trial of anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase"

2009-2011 Principal Investigator for OHSU study #5363, "ESPIRIT: A 10-year, postmarketing observational registry of Humira® (adalimumab) in adult patients with chronic plaque psoriasis"

2011-2016 Principal Investigator, "A dose-ranging and efficacy study of LY2439821 (an anti-IL-17 antibody) in patients with moderate-to-severe psoriasis"

2011-2013 Principal Investigator, "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after 12 weeks of treatment, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis (ERASURE)"

2011-2012 Sub-Investigator, "A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis"

2011-2012 Sub-Investigator, "A phase 3 multicenter, randomized, double-blind, placebo-controlled, trial of ustekinumab, a fully human anti-IL-12/23p40 monoclonal antibody, administered subcutaneously, in subjects with active psoriatic arthritis (PSUMMIT I)"

2011-2012 Sub-Investigator, "A phase 3 multicenter, randomized, double-blind, placebo-controlled, trial of ustekinumab, a fully human anti-IL-12/23p40 monoclonal antibody, administered subcutaneously, in subjects with active psoriatic arthritis including those previously

- 2011-2012 treated with biologic anti TNF α agent(s) (PSUMMIT II)
Sub-Investigator, "A multicenter, randomized, double-blind, placebo-controlled evaluation of rosacea-related inflammatory biochemical markers in the skin of adults with papulopustular rosacea treated with daily doxycycline 40 mg (30 mg immediate release/10 mg delayed releases beads) capsules"
- 2011-2012 Sub-Investigator, "A randomized, double-blind, vehicle-controlled, multicenter, parallel group study of the safety and efficacy of terbinafine nail lacquer 3% in the treatment of mild to moderate distal subungual onychomycosis of the toenails for 52 weeks"
- 2011-2012 Sub-Investigator, "A randomized, double-blind, vehicle-controlled, multi-center study to evaluate the efficacy and safety of AN2690 topical solution, 5%, vs. solution vehicle in the treatment of onychomycosis of the toenails in adults"
- 2011-2012 Sub-Investigator, "A multicenter, randomized, double-blind, parallel-group study to evaluate the safety and efficacy of bimatoprost solution 0.03%, 0.1%, and 0.3% compared with vehicle in men with androgenic alopecia with an open-label active comparator (minoxidil 5%) group"
- 2011-2012 Sub-Investigator, "A multicenter, randomized, double-blind, parallel-group study to evaluate the safety and efficacy of bimatoprost solution 0.03%, 0.1%, and 0.3% compared with vehicle in women with female pattern hair loss with an open-label active comparator (minoxidil 2%) group"
- 2011 Sub-Investigator, "A multicenter, double-blind, randomized, placebo-controlled, parallel-group extension study to evaluate the safety and efficacy of BOTOX $\text{\textcircled{R}}$ (botulinum toxin type A) purified neurotoxin complex in subjects with facial rhytides (crow's feet lines and glabellar lines)"
- 2011 Sub-Investigator, "A pivotal USA randomized, evaluator-blinded, active-controlled, multi-center, split-face comparison study of Emervel Classic Lidocaine versus Juvederm $\text{\textcircled{R}}$ Ultra in the treatment of moderate to severe facial wrinkles and folds"
- 2011-2017 Principal Investigator, "A multicenter study with a randomized, double-blind, placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis "
- 2011-2013 Sub-Investigator, "An open-label extension study to evaluate the safety of etanercept in pediatric subjects with plaque psoriasis"
- 2012-2013 Sub-Investigator, "A phase 2 multicenter, randomized, placebo- and active-comparator-controlled, dose-ranging trial to evaluate CNTO 1959 for the treatment of subjects with moderate to severe plaque-type psoriasis (X-PLORE)"

- 2012 Sub-investigator, "A phase II study of photodynamic therapy with Levulan topical solution plus blue light versus Levulan topical solution vehicle plus blue light using spot and broad area application and incubation times of 1, 2 and 3 hours for the treatment of multiple actinic keratoses on the face or scalp"
- 2012 Sub-investigator, "A double-blind, randomized, parallel-group, vehicle-controlled, multicenter study to evaluate the safety and bioequivalence of a generic butenafine HCl cream, 1% and reference listed Lotrimin Ultra (butenafine HCl cream, 1%) and compare both active treatments to a vehicle control in the treatment of interdigital tinea pedis"
- 2012-2015 Principal Investigator, "A phase 3b, randomized, double-blind, active-controlled, multicenter study to evaluate a "subject-tailored" maintenance dosing approach in subjects with moderate-to-severe plaque psoriasis (PSTELLAR)"
- 2012-2013 Sub-investigator, "A sequential treatment regimen of cryotherapy and Picato (ingenol mebutate) gel, 0.015% field therapy compared to cryotherapy alone for the treatment of actinic keratosis on the face and scalp"
- 2012-2013 Sub-Investigator, "A randomized, phase 2, double-blind, placebo-controlled trial to evaluate the safety and efficacy of HL-009 liposomal gel in adult patients with mild to moderate atopic dermatitis"
- 2012-2013 Principal Investigator, "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after 12 weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis (FEATURE)"
- 2012-2014 Sub-Investigator, "Safety and efficacy of luliconazole solution, 10% with two dosing regimens in distal subungual onychomycosis of the toenails: a randomized, double-blind, vehicle-controlled, phase 2b/3 study"
- 2012-2013 Sub-Investigator, "A multicenter, randomized, double-blind, four-week, bilateral study of the safety and efficacy of two concentrations of AN2728 ointment administered once or twice a day in adolescents with atopic dermatitis"
- 2012-2015 Principal Investigator, "A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab"
- 2012-2013 Sub-Investigator, "A randomized, double-blind, parallel-group, vehicle-controlled, multicenter study comparing imiquimod cream, 3.75% generic to reference listed drug in the treatment of actinic keratosis of the face or balding scalp"

2012-2019	Principal Investigator, "A 12-week multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2439821 to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period"
2012	Sub-Investigator, "A parallel-group, vehicle-controlled, randomized, double-blind study of the efficacy and safety of product 49778 and product 10156 in subjects with seborrheic dermatitis"
2012-2015	Principal Investigator, "A phase 3 study to evaluate the efficacy, safety, and effect of withdrawal and retreatment with brodalumab in subjects with moderate to severe plaque psoriasis: AMAGINE-1"
2012-2013	Sub-Investigator, "An open-label, multicenter study of the efficacy of Cloderm cream (clocortolone pivalate, 0.1%) in the treatment of moderate plaque psoriasis for 28 days"
2013	Sub-Investigator, "Oxymetazoline HCl cream for the treatment of erythema associated with rosacea"
2013-2019	Principal Investigator, "A 52-week, phase 3, randomized, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis"
2013-2014	Sub-Investigator, "Bimatoprost for the treatment of eyebrow hypotrichosis"
2013	Principal Investigator, "A multicenter, randomized, double-blind, parallel group comparison of halobetasol propionate lotion 0.05% versus vehicle lotion in subjects with plaque psoriasis"
2013-2014	Principal Investigator, "A phase 2B, multi-site, randomized, double-blind, vehicle-controlled, parallel-group study of the efficacy, safety, local tolerability and pharmacokinetics of 2 dose strengths and 2 regimens of tofacitinib ointment in subjects with chronic psoriasis"
2013-2014	Principal Investigator, "A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety, pharmacokinetic and biomarker profiles of REGN668 administered to adult patients with moderate-to-severe atopic dermatitis"
2013	Principal Investigator, "Qualitative interviews for the development of a patient-reported outcome (PRO) measure in patients with seborrheic keratosis (phase I)"
2013-2014	Principal Investigator, "A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to determine the therapeutic equivalence of generic imiquimod cream, 2.5% and Zyclara® (imiquimod) cream, 2.5% in subjects with actinic keratoses"
2014	Principal Investigator, "A phase 2, randomized, double-blind, vehicle controlled, dose-ranging study of the effect of DRM04B in subjects with axillary hyperhidrosis"
2014-2015	Principal Investigator, "A phase 2 randomized, double-blind, vehicle-controlled, dose-ranging study to investigate the efficacy and safety of ME1111 in patients with mild to moderate onychomycosis"

2014	Sub-Investigator, "Safety and efficacy of bimatoprost solution versus vehicle in men with androgenic alopecia"
2014	Principal Investigator, Efficacy and safety of ingenol mebutate gel 0.06% when applied once daily for 2, 3 or 4 consecutive days to a treatment area of approximately 250 cm ² on trunk and extremities in subjects with actinic keratosis: an international, phase 2, randomized, multicentre, double-blind, vehicle-controlled, 8-week trial"
2014	Principal Investigator, "Qualitative interviews for the development of a patient-reported outcome (PRO) measure in patients with seborrheic keratosis (phase II)"
2014-2017	Principal Investigator, "An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab trials"
2014-2015	Principal Investigator, "A 48 week study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)"
2014-2015	Sub-Investigator, "A long-term safety and efficacy study of oxymetazoline HCl cream 1.0% in patients with persistent erythema associated with rosacea"
2014-2016	Principal Investigator, "A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to determine efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis"
2014	Sub-Investigator, "Exploratory genetic study in subjects with moderate to severe psoriasis"
2014	Sub-Investigator, "Efficacy and safety of oxymetazoline HCl cream 1.0% for the treatment of persistent erythema associated with rosacea"
2014	Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile of A-101 topical solution in subjects with seborrheic keratosis"
2014-2015	Principal Investigator, "A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to severe chronic plaque-type psoriasis"
2014-2015	Principal Investigator, "A randomized, double-blind, placebo-controlled, study investigating vaccine responses in adults with moderate to severe atopic dermatitis treated with dupilumab"
2014-2015	Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile of A-101 solution in subjects with seborrheic keratosis of the face"
2014-2016	Principal Investigator, "A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis"

2014-2016	Principal Investigator, “A phase 3, multicenter, randomized, double-blind study to evaluate the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab”
2014-2015	Principal Investigator, “A phase 2, multicenter, randomized, double-blind, vehicle-controlled study on the safety, tolerability, and efficacy of 0.15% and 0.25% concentrations of topical SM04554 solution in male subjects with androgenetic alopecia (AGA)”
2014-2016	Principal Investigator, A randomized, double-blind, placebo-controlled study of the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum”
2014-2016	Principal Investigator, “A 2-year, open-label, safety extension study of gevokizumab in patients with pyoderma gangrenosum”
2014-2018	Principal Investigator, “A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis”
2014-2018	Principal Investigator, “A phase 3, multicenter, randomized, double-blind placebo and active comparator-controlled study evaluating the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis”
2014-present	Principal Investigator, “An open label extension trial assessing the safety and efficacy of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis”
2015-2017	Principal Investigator, “A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail”
2015	Study Investigator, “A test of seborrheic keratosis physician lesion assessment reliability”
2015	Principal Investigator, “A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis”
2015	Principal Investigator, “A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study to compare Perrigo UK FINCO’s brimonidine topical gel 0.33% to Mirvaso® (brimonidine) topical gel 0.33%, and both active treatments to a vehicle control in the treatment of persistent (non-transient) facial erythema of rosacea”
2015	Principal Investigator, “A multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects”
2015-2016	Principal Investigator, “An open-label phase II study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with persistent, moderate to severe atopic dermatitis”
2015-2016	Principal Investigator, “A double-blind extension study to evaluate the

	post-treatment safety and duration of clinical effect of LIPO-202 in subjects who complete either the LIPO-202-CL-18 or LIPO-202-CL-19 study”
2015-2016	Principal Investigator, “A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab dosing regimens in patients with moderate-to-severe plaque psoriasis”
2015-2016	Principal Investigator, “A randomized, double-blind, vehicle-controlled, parallel group study of the safety, tolerability, bioavailability and dose-response of ALX-101 topical gel administered twice daily in adult subjects with mild to moderate atopic dermatitis (ALX-101-ATOP-201)”
2015-2016	Principal Investigator, “A phase 3, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of IDP-118 in the treatment of plaque psoriasis (V01-118A-302)”
2015-2016	Principal Investigator, “A phase 3, multicenter, open label study to evaluate the long-term safety of IDP-118 lotion in the treatment of plaque psoriasis (V01-118A-303)”
2015-2018	Principal Investigator, “A phase 3, multicenter, randomized, double-blind, parallel-group, placebo-and-active-controlled study followed by a placebo-controlled maintenance period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis”
2016	Principal Investigator, “A randomized, double-blind, vehicle-controlled, parallel group study of the safety and effectiveness of A-101 solution 40% in subjects with seborrheic keratosis on the trunk, extremities and face (study 2)”
2016-2018	Principal Investigator, “A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis”
2016-2018	Principal Investigator, “BI 655066 versus ustekinumab and placebo comparators in a randomized double blind trial for maintenance use in moderate to severe plaque type psoriasis (UltIMMa-1)”
2016-2018	Principal Investigator, “BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance)”
2016-2018	Principal Investigator, “A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis”
2016-2018	Principal Investigator, “A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab,

	and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY)”
2016-2017	Principal Investigator, “A phase 2 randomized, double-blind, placebo-controlled, parallel-cohort study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of once-daily application of topical VDA-1102 ointment for 28 days in subjects with actinic keratosis”
2016-2017	Principal Investigator, “A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bimekizumab in adult subjects with moderate-to-severe chronic plaque psoriasis”
2016-2018	Principal Investigator, “A phase 2B, multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate-to-severe chronic plaque psoriasis”
2016-2018	Principal Investigator, “A phase IIA, randomized, double-blind, placebo-controlled study of the safety and efficacy of varying regimens of CANDIN for treatment of common warts (verruca vulgaris)”
2016-2017	Principal Investigator, “Phase 2 study of RVT-501 in adult and adolescent subjects with atopic dermatitis”
2017-2018	Principal Investigator, “A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of mepolizumab administered subcutaneously in subjects with moderate to severe atopic dermatitis”
2017-present	Principal Investigator, “A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)”
2017-2018	Principal Investigator, “An open-label, randomized, actual use study of dupilumab auto-injector device in patients with atopic dermatitis”
2017-2018	Principal Investigator, “Multicenter, randomized, double-blind, placebo-controlled, phase 2A study of setipiprant tablets in androgenetic alopecia in males with a comparator arm”
2017-2019	Principal Investigator, “A randomized, double-blind, placebo-controlled, parallel group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO)”
2017-2018	Principal Investigator, “A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab monotherapy in patients >12 to <18 years of age, with moderate-to-severe atopic dermatitis”
2017-2018	Principal Investigator, “An open-label, multi-center trial to assess the safety of single and repeat treatments of daxibotulinumtoxinA for injection for treatment of moderate to severe glabellar lines (SAKURA OPEN LABEL SAFETY)”
2017-present	Principal Investigator, “A phase IV, open label study of the effects of

	apremilast on vascular inflammation and cardiometabolic function in psoriasis”
2017-present	Principal Investigator, “A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy”
2017-2019	Principal Investigator, “An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients >6 months to <18 years of age with atopic dermatitis”
2017-2019	Principal Investigator, “A phase 3, double-blind, vehicle-controlled, randomized, parallel group, multicenter, efficacy and safety study of KX2-391 ointment 1% in adult subjects with actinic keratosis on the face or scalp”
2017-2018	Principal Investigator, “A randomized, double-blind, placebo-controlled, phase 2b, multicenter study to evaluate the safety, efficacy, and tolerability of SNA-120 in subjects with pruritus associated with psoriasis vulgaris”
2017-2018	Sub-Investigator, A phase2b/3 randomized, double-blind, placebo controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer’s dementia”
2018	Principal Investigator, “Randomized, double-blind, vehicle-controlled, multicenter, parallel-group, phase 2a study to assess the safety and efficacy of PR022 topical gel in adults with mild to moderate atopic dermatitis”
2018-present	Principal Investigator, “A phase 3, multicenter, double-blind, placebo-controlled study with an initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”
2018	Principal Investigator, “Phase 2 study to evaluate the efficacy, safety, and tolerability of RVT-501 topical ointment in pediatric patients with mild to moderate atopic dermatitis”
2018-2019	Principal Investigator, “A randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis”
2018-2019	Principal Investigator, “A multicenter study with a randomized, double-blind, placebo-controlled induction dosing period followed by a randomized withdrawal maintenance dosing period to evaluate the efficacy and safety of mirikizumab in patients with moderate-to-severe plaque psoriasis: OASIS-1”
2018-present	Principal Investigator, “A multicenter, randomized, open label, efficacy assessor-blinded study of risankizumab compared to secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy”

2018-2019	Sub-Investigator, “A phase 2B open-label study to evaluate the efficacy, safety, and tolerability of topical VDA-1102 ointment in subjects with actinic keratosis”
2018-present	Principal Investigator, “A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects”
2018-present	Principal Investigator, “A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”
2018-present	Principal Investigator, “A phase 3 multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis”
2018-present	Principal Investigator, “An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials”
2018-present	Principal Investigator, “A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”
2018-present	Principal, Investigator, “A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis”
2018-2019	Principal Investigator, “A randomized, double-blind, placebo-controlled multicenter study to evaluate the safety, tolerability and efficacy of ATI-501 oral suspension compared to placebo in adult subjects with alopecia areata, alopecia universalis, or alopecia totalis”
2018-present	Sub-Investigator, “A phase 2, multicenter, randomized, placebo controlled, double-blind, proof-of-concept study to evaluate guselkumab for the treatment of subjects with moderate to severe hidradenitis suppurativa”
2018-present	Principal Investigator, “A 24-week multicenter, randomized, double-blind, parallel-group study comparing the efficacy and safety of ixekizumab to guselkumab in patients with moderate-to-severe plaque psoriasis”
2019-present	Sub-Investigator, “Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczema”
2019-present	Principal Investigator, “A multi-center, randomized, double-blind, placebo- and active comparator-controlled phase 3 study to evaluate the efficacy and safety of BMS-986165 in subjects with moderate-to-severe plaque psoriasis”

2019-present	Principal Investigator, "A multicenter, randomized, double-blind, placebo controlled, operationally seamless, adaptive phase 2/3 study to evaluate the efficacy and safety of baricitinib in adult patients with severe or very severe alopecia areata"
2019	Principal Investigator, "Open-label study of ATI-502 topical solution for the treatment of alopecia areata, alopecia universalis, and alopecia totalis"
2019-present	Principal Investigator, "A phase 3, multi-center, randomized, double-blind, vehicle-controlled, parallel group study comparing the efficacy and safety of SB206 and vehicle gel once daily in the treatment of molluscum contagiosum"
2019-present	Principal Investigator, "A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults"
2019-present	Principal Investigator, "A long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults"
2019-present	Principal Investigator, "A phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis"
2019-present	Principal Investigator, "A multicenter, randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe plaque psoriasis of the scalp"
2019-present	Principal Investigator, "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis"
2019-present	Principal Investigator, "A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of ruxolitinib cream followed by an extension period in participants with vitiligo"

Research Grants:

1989-1993	"Intralesional Cyclosporine for Alopecia Totalis," Principal Investigator, Alopecia Areata Foundation Research Grant, \$15,000
1996-2004	"Immunologic and virologic studies of the skin with particular relevance to HIV disease and Kaposi's sarcoma pathogenesis," continual NIH intramural funding with increasing yearly budgets based upon outstanding evaluations by internal and external review panels
1998-2000	"Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis," Principal Investigator, NCI Division of Clinical Sciences Intramural Research Award, \$100,000/year
1999-2006	"Topical Agents to Prevent Mucosal HIV Transmission," Co-Investigator, NIH extramural Program Project #AI51649

2000-2002	"Novel Transgenic Mouse Models of Kaposi's Sarcoma," Principal Investigator, NCI Division of Clinical Sciences Intramural Research Award, \$75,000/year
2004	"Topical Agents to Prevent Mucosal HIV Transmission," Principal Investigator, James B. Pendleton Charitable Trust, \$75,400
2005-2006	"Efalizumab for Moderate to Severe Atopic Dermatitis- A Phase I Pilot Study in Adults," Principal Investigator for laboratory based studies, Genentech, \$25,000
2006-2007	"The Role of IL-23 in the Pathogenesis of Psoriasis," Principal Investigator, National Psoriasis Foundation Research Grant, \$30,000
2006-2007	"Psoriasis as a T IL-17 Autoimmune Skin Disease?" Principal Investigator, Oregon Medical Research Foundation, \$30,000
2007-2010	"Psoriasis-like Disease Induced by TGF β 1 and IL-23," Principal Investigator, Veterans Affairs Merit Award, \$375,000
2007	"Psoriasis-like Disease Induced by IL-23," Principal Investigator, American Skin Association, \$15,000
2007-2009	"Role of IL-23 in Psoriasis Pathogenesis," Principal Investigator, National Institutes of Health 1 R21 AR054495-01A1, \$275,000
2008-2009	"Investigating the IL-23/IL-17 Inflammatory Pathway in Psoriasis Patients Receiving Remicade Therapy," Principal Investigator, Centocor, \$67,400
2008-2009	"Psoriasis fellow support," Principal Investigator, Abbott, \$45,000
2009-2011	"Trim32 Regulation of Piasy in Skin Homeostasis," Co-investigator (3% effort), National Institutes of Health R01 AR055651
2009-2011	"Training in the Molecular Basis of Skin/Mucosa Pathobiology," Associate Program Director, National Institutes of Health T32 CA106195-06A1
2009-2011	"Comparative Effectiveness of Biologics for Psoriasis," Steering Committee Member, National Institutes of Health RC1 ARO58204
2009-2010	" <i>Candida albicans</i> as a potential immunologic trigger for psoriasis," Principal Investigator, Oregon Medical Research Foundation, \$40,000
2011-2016	"HIV-1 R5 Envelope Determinants and Properties that Affect Transmission," Significant Contributor, National Institutes of Health R01

Consulting Activities:

2003	Consultant, FDA Center for Drug Evaluation and Research
2004	Scientific Consultant, Genentech
2004-2007	Medical Advisory Board, Coria Laboratories, Ltd.
2005-present	Scientific Advisory Board, Maui Derm annual meeting
2005-2008	Consultant, MEDACorp
2005-present	Scientific Consultant, Centocor, Inc./Janssen
2005-2008	Dermatology National Faculty Speaker's Bureau, Centocor, Inc.
2006-2011	Scientific Consultant, Anacor Pharmaceuticals
2006-2008	Member, The Society of Industry Leaders

2006-present	Scientific Consultant, Abbott Laboratories, Inc./AbbVie
2006-2008	Speaker Board, Abbott Laboratories, Inc.
2006-2008	Speaker Board, Amgen
2006-2008	Member, Medical Education Speakers Network
2007	Consultant, CVS Pharmacy
2007	Medical Consultant, Barrier Therapeutics, Inc.
2007	Medical Consultant, Emeritus Educational Sciences
2007	Scientific Consultant, CombinatoRx
2007	Scientific Consultant, Cerimon Pharmaceuticals
2007-present	Scientific Consultant, Eli Lilly and Company
2007-2010	Scientific Consultant, MacroGenics, Inc.
2008	Scientific Consultant, PM Toleikis & Associates Consulting, Inc.
2008-present	Scientific Consultant, Amgen
2008	Scientific Consultant, Vascular Biogenics, Ltd.
2008-2013	Invited Member, Scientific Steering Committee for phase 4 PSUNRISE study, Centocor
2009-2011	Invited Member, Scientific Steering Committee for phase 4 ESPRIT study, Abbott
2010-2012	Scientific Consultant, Takeda Pharmaceuticals
2010	Scientific Consultant, Artielle Immunotherapeutics
2010-2012	Invited Key Informant, Federal Advisory Panel of the Agency for Healthcare Research and Quality on "Biologic and Non-biologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis"
2010-present	Invited Member, Scientific Steering Committee for phase 3 secukinumab psoriasis studies, Novartis
2010-present	Scientific Consultant, Novartis
2010-present	Scientific Consultant, Pfizer
2010-present	Scientific Consultant, Boehringer Ingelheim
2011-present	Medical Advisor, Ultra
2011-2016	Invited Lead Member, Scientific Steering Committee for phase 3B PSTELLAR study, Janssen
2012-2019	Dermatology National Faculty Speaker's Bureau, Janssen
2012	Scientific Consultant, Maruho
2012-present	Scientific Consultant, Allergan
2013-present	Scientific Consultant, Regeneron
2013-present	Invited Member, Lilly Autoimmune Strategic Advisory Board
2013-present	Invited Member, Lilly Global Advisory Board for ixekizumab
2013	Scientific Consultant, Baxter
2013-present	Scientific Consultant, Merck
2013	Scientific Consultant, Momenta
2013-present	Scientific Consultant, Celgene
2014-present	Invited Member, Scientific Steering Committee for phase 3 guselkumab psoriasis studies, Janssen
2014	Scientific Consultant, Samumed
2014-present	Scientific Consultant, Galderma

2015-present	Invited Member, Scientific Steering Committee for phase 3 BI 655066 psoriasis studies, Boehringer Ingelheim
2015-present	Invited Member, Publication Committee for phase 3 BI 655066 psoriasis studies, Boehringer Ingelheim
2015-present	Scientific consultant, Dermira
2015-present	Scientific consultant, Genentech
2015-present	Scientific consultant, Sanofi Genzyme
2015-present	Chair, Efficacy Subcommittee, Lilly Global Medical Education Steering Committee
2016-2018	Lilly National Speaker Board
2016-present	Scientific consultant, Valeant
2016-present	Scientific consultant, MedImmune/AstraZeneca
2016-present	Scientific consultant, UCB
2016-present	Scientific consultant, Sun Pharma
2016-present	Scientific consultant, Sandoz
2016-present	Scientific consultant, Gilead
2017-present	Scientific consultant, Purdue Pharma
2017-present	Scientific consultant, Roivant Sciences
2017-present	Scientific consultant, Almirall
2017-present	Scientific consultant, 23andMe
2017-present	Scientific consultant, Vidac
2017-present	Scientific consultant, Sienna Pharmaceuticals
2017-present	Regeneron/Sanofi Genzyme National Speaker Board
2017-present	Scientific consultant, Meiji
2018-present	Scientific consultant, Akros
2018-present	Scientific consultant, Arena
2018-present	Scientific consultant, Bristol-Myers Squibb
2019-present	Scientific consultant, FLX Bio
2019-present	Speaker Board, AbbVie
2019-present	Scientific consultant, Forte
2019-present	Scientific consultant, Serono

Mentorship:

- Primary mentor to 9 laboratory research-based postdoctoral fellows (2 with Ph.D.: Drs. J. Paul Zoetewij, Erin Harper; 2 with M.D.: Drs. Nickolai Talanin, Andrea Niedermeier; and 5 with M.D., Ph.D.: Drs. Tatsuyoshi Kawamura, Takahiro Watanabe, Makoto Sugaya, Wei Liao, Shinji Kagami)
 - 4 currently in independent academic positions, with 2 in chairman positions (Drs. Kawamura, Sugaya, Niedermeier, Liao)
 - 2 currently in industry (Drs. Zoetewij and Harper)
 - 3 currently in private practice dermatology (Drs. Watanabe, Talanin, Kagami)
- Mentor to 8 clinical research-based postdoctoral fellows (7 with M.D.: Drs. Alexa Kimball, Allison Ehrlich, Edward Cowen, Gretchen Vanderbeek, Jennifer Lee, Aman Samrao, Brian Truong, Alison Uyemura)
 - 4 currently in independent academic positions, with 3 in chair/leadership positions with (Drs. Kimball, Ehrlich, Cowen, Samrao)

- 4 currently in private practice (Drs. Vanderbeek, Lee, Truong, Uyemura)
- Primary mentor to 9 students performing laboratory research before or during medical/graduate school
 - 2 went on to train in dermatology and currently in independent academic positions (Drs. Sharon Jacob and Aparche Yang)
 - 4 went on to train in dermatology and currently in private practice dermatology (Drs. April Atkins, Stacey Reed, Sam Bremmer, Ryan Sells)
 - 1 currently in dermatology residency (Ms. Erin Foster)
 - 2 currently in graduate school (Ms. Iliyana Mikell, Ms. Heather Rizzo)

Honors/Awards:

1980	Phi Eta Sigma (Freshmen Engineering Honor Society)
1983	Eta Kappa Nu (Electrical Engineering Honor Society)
1983	Tau Beta Pi (Engineering Honor Society)
1983	Golden Key (Leadership Honor Society)
1983	Mortar Board (Leadership Honor Society)
1984	Mortar Board Graduate Fellowship
1988	Alpha Omega Alpha
1992	University of Miami George Ioannides Award for Excellence in Resident Teaching
1996	American Academy of Dermatology Young Investigator in Dermatology Award
1999	U.S. Public Health Service Outstanding Service Medal
2000	Invited participant for “The Biology of HIV Transmission” NIH Think Tank
2001	Invited participant for “Antigen Presenting Cells in HIV Pathogenesis and Therapy” NIH Think Tank
2004	Elected member, American Society for Clinical Investigation
2007	Elected member, American Dermatological Association
2007	OHSU Department of Dermatology Faculty Award for Teaching
2007	OHSU Rose Award for Outstanding Service Excellence by a patient, visitor, or colleague
2008	National Psoriasis Foundation Certificate of Appreciation for outstanding advocacy service to the psoriasis community
2008	OHSU Department of Medicine Career Teaching Achievement Award
2008	University of Massachusetts John R. Person Lecturer in Dermatology
2008	University of Washington Robert Pommerening Lecturer in Dermatology
2011	Dermatology Nurses’ Association First Annual Robin Weber Memorial Immunology Lecture
2011	OHSU Department of Dermatology Faculty Award for Teaching
2011	Invited Councilor, International Psoriasis Council
2012	University of Toronto Ricky K. Schachter Lecturer in Psoriasis
2013	Invited member, Noah Worcester Dermatological Society
2017	University of Cincinnati Smith H. & Lucille Gibson, M.D., Endowed Lecture in Dermatology
2017	Volunteer of the Year, International Psoriasis Council
2019	Invited Councilor, International Eczema Council

Bibliography-Scientific Articles:

1. Zhu WY, Blauvelt A, Goldstein BA, Leonardi CL, Penneys NS. Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro with liquid nitrogen, trichloroacetic acid, and podophyllin. **J Am Acad Dermatol** 1992;26:710-714.
2. Zhu WY, Leonardi CL, Blauvelt A, Serfling U, Penneys NS. Human papillomavirus DNA in the dermis of condyloma acuminatum. **J Cutan Pathol** 1993;20:447-450.
3. Penneys NS, Leonardi CL, Cook S, Blauvelt A, Rosenberg S, Eells LD, Konwiser M, Aaronson CM. Identification of *Mycobacterium tuberculosis* DNA in five different types of cutaneous lesions by the polymerase chain reaction. **Arch Dermatol** 1993;129:1594-1598.
4. Blauvelt A, Katz SI, Udey MC. Human Langerhans cells express E-cadherin. **J Invest Dermatol** 1995;104:293-296.
5. Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, Walker R, Shearer GM, Katz SI. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. **J Immunol** 1995;154:3506-3515.
6. Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. **J Immunol** 1995;154:4851-4856.
7. Blauvelt A, Chougnet C, Shearer GM, Katz SI. Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12. **J Clin Invest** 1996;97:1550-1555.
8. Blauvelt A, Asada H, Klaus-Kovtun V, Altman DJ, Lucey DR, Katz SI. Interleukin-15 mRNA is expressed by human keratinocytes, Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. **J Invest Dermatol** 1996;106:1047-1052.
9. Enk CD, Mahanty S, Blauvelt A, Katz SI. UVB induces IL-12 transcription in human keratinocytes *in vivo* and *in vitro*. **Photochem Photobiol** 1996;63:854-859.
10. Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein MD, Ganem D, Herndier B. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. **AIDS** 1997;11:F35-F45.
11. Blauvelt A, Sei S, Cook PM, Schulz TF, Jeang KT. Human herpesvirus 8 infection occurs following adolescence in the United States. **J Infect Dis** 1997;176:771-774.

12. Blauvelt A, Asada H, Saville MW, Klaus-Kovtun V, Altman DJ, Yarchoan R, Katz SI. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. **J Clin Invest** 1997;100:2043-2053.
13. Blauvelt A, Herndier BG, Orenstein JM. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma (letter). **N Engl J Med** 1997;336:1837-1838.
14. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. **Nat Med** 1997;3:1369-1375.
15. Zoetewij JP, Golding H, Mostowski H, Blauvelt A. Cutting edge: cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells. **J Immunol** 1998;161:3219-3223.
16. Cohen SS, Weinstein MD, Herndier BG, Anhalt GJ, Blauvelt A. No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. **J Invest Dermatol** 1998;111:781-783.
17. Asada H, Klaus-Kovtun V, Golding H, Katz SI, Blauvelt A. Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfecting cultures. **J Virol** 1999;73:4019-4028.
18. Zoetewij JP, Eyes ST, Orenstein JM, Kawamura T, Wu L, Chandran B, Forghani B, Blauvelt A. Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. **J Virol** 1999;73:5894-5902.
19. Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E, Blauvelt A, Shearer GM. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. **J Immunol** 1999;163:1666-1673.
20. Papadopoulos EJ, Sasseti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, Saraf MA, Schall T, Blauvelt A, Rosen SD, Hwang ST. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. **Eur J Immunol** 1999;29:2551-2559.
21. Anderson HA, Bergstralh DT, Kawamura T, Blauvelt A, Roche PA. Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen processing compartments. **J Immunol** 1999;163:5435-5443.
22. Lehrnbecher T, Foster CB, Zhu S, Venzon D, Steinberg SM, Wyvill K, Metcalf JA, Cohen SS, Kovacs J, Yarchoan R, Blauvelt A, Chanock SJ. Variant genotypes of *FcR11A* influence the development of Kaposi's sarcoma in HIV-infected men. **Blood** 2000;95:2386-2390.

23. Blauvelt A, Glushakova S, Margolis LB. HIV-infected human Langerhans cells transmit infection to human lymphoid tissue *ex vivo*. **AIDS** 2000;14:647-651.
24. Wu SJL, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Bix DL, Hayes CG, Frankel SS. Human skin Langerhans cells are targets of dengue virus infection. **Nat Med** 2000;6:816-820.
25. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ. An *IL6* promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. **Blood** 2000;96:2562-2567.
26. Orenstein JM, Ciufu DM, Zoetewij JP, Blauvelt A, Hayward GS. Morphogenesis of HHV8 in primary human dermal microvascular endothelium and primary effusion lymphomas. **Ultrastruct Pathol** 2000;24:291-300.
27. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. **J Exp Med** 2000; 192:1491-1500.
28. Kawamura T, Qalbani M, Thomas EK, Orenstein JM, Blauvelt A. Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF- β 1 and increased viral replication with CD40 ligand-induced maturation. **Eur J Immunol** 2001;31:360-368.
29. Zoetewij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, Yarchoan R, Orenstein JM, Blauvelt A. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. **Blood** 2001;97: 2374-2380.
30. Davis DA, Rinderknecht AS, Zoetewij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, Yarchoan R. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. **Blood** 2001;97:3244-3250.
31. Zoetewij JP, Rinderknecht AS, Davis DA, Yarchoan R, Blauvelt A. Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines. **J Med Virol** 2002;66:378-383.
32. Zaitseva M, Kawamura T, Loomis R, Goldstein H, Blauvelt A, Golding H. Stromal-derived factor 1 expression in the human thymus. **J Immunol** 2002;168:2609-2617.
33. Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, Blauvelt A. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. **J Invest Dermatol** 2002;119:793-797.

34. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. **J Virol** 2003;77:1021-1038.
35. Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. **J Immunol** 2003;170:4260-4266.
36. Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, Borris DL, Brady J, Blauvelt A. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. **J Virol** 2003;77: 6188-6196.
37. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound *CCR5* polymorphisms. **Proc Natl Acad Sci U S A** 2003;100:8401-8406.
38. Sugaya M, Lore K, Koup RA, Douek DC, Blauvelt A. HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. **J Immunol** 2004;172:2219-2224.
39. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ, Belisle JT, Blauvelt A, Porcelli SA, Modlin RL. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. **J Clin Invest** 2004;113: 701-708.
40. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of *CCR5* diplotypes. **J Virol** 2004;78:7602-7609.
41. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. **Science** 2004;306:485-487.
42. Sugaya M, Watanabe T, Yang A, Starost MF, Kobayashi H, Atkins AM, Borris DL, Hanan EA, Schimel D, Bryant MA, Roberts N, Skobe M, Staskus KA, Kaldis P, Blauvelt A. Lymphatic dysfunction in transgenic mice expressing KSHV *k-cyclin* under the control of the VEGFR-3 promoter. **Blood** 2005;105:2356-2363.
43. Klase Z, Donio MJ, Blauvelt A, Marx PA, Jeang KT, Smith SM. A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames. **Retrovirology** 2006;3:1.

44. Niedermeier A, Talanin N, Chung EJ, Sells RE, Borris DL, Orenstein JM, Trepel JB, Blauvelt A. Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. **J Invest Dermatol** 2006;126:2516-2524.
45. Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, Hwang ST. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. **J Immunol** 2006;177:7665-7672.
46. Sugaya M, Hartley O, Root MJ, Blauvelt A. C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells. **J Invest Dermatol** 2007;127:1436-1443.
47. Harper EG, Simpson EL, Takiguchi RH, Boyd MD, Kurtz SE, Bakke AC, Blauvelt A. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. **J Invest Dermatol** 2008;128:1173-1181.
48. Kawamura T, Koyanagi Y, Nakamura Y, Ogawa Y, Yamashita A, Iwamoto T, Ito M, Blauvelt A, Shimada S. Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. **J Immunol** 2008;180:3297-3304.
49. Ogawa Y, Kawamura T, Kimura T, Ito M, Blauvelt A, Shimada S. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. **Blood** 2009;113:5157-5166.
50. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A. Th17 cytokines stimulate CCL20 expression in keratinocytes *in vitro* and *in vivo*: implications for psoriasis pathogenesis. **J Invest Dermatol** 2009;129:2175-2183.
51. Fitch EL, Rizzo HL, Kurtz SE, Wegmann KW, Gao W, Benson JM, Hinrichs DJ, Blauvelt A. Inflammatory skin disease in *K5.hTGF-β1* transgenic mice is not dependent upon the IL-23/Th17 inflammatory pathway. **J Invest Dermatol** 2009;129:2443-2450.
52. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. **J Invest Dermatol** 2010;130:1373-1383.
53. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. IL-17 is essential for host defense against cutaneous *Staphylococcus aureus* infection in mice. **J Clin Invest** 2010;120:1762-1773.
54. Lillis JV, Guo CS, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. **Arch Dermatol** 2010;146:918-919.

55. Kagami S, Rizzo HL, Kurtz SE, Miller LS, [Blauvelt A](#). IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against *Candida albicans*. **J Immunol** 2010;185:5453-5462.
56. Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, [Blauvelt A](#). IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. **J Immunol** 2011;186:1495-1502.
57. Sugaya M, Reed S, Rose PP, de la Motte S, Raggio CM, Kurtz SE, Moses AV, Früh K, [Blauvelt A](#). Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21. **J Dermatol Sci** 2011;61:139-142.
58. Miyagaki T, Sugaya M, Okochi H, Asano Y, Tada Y, Kadono T, [Blauvelt A](#), Tamaki K, Sato S. Blocking MAPK signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses. **J Invest Dermatol** 2011;131:1927-1935.
59. Sugaya M, Kuwano Y, Suga H, Miyagaki T, Ohmatsu H, Kadono T, Okochi H, [Blauvelt A](#), Tamaki K, Sato S. Lymphatic dysfunction impairs antigen-specific immunization, but augments tissue swelling following contact with allergens. **J Invest Dermatol** 2012;132:667-676.
60. Ogawa Y, Kawamura T, Matsuzawa T, Aoki R, Gee P, Yamashita A, Moriishi K, Yamasaki K, Koyanagi Y, [Blauvelt A](#), Shimada S. Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. **Cell Host Microbe** 2013;13:77-86.
61. Kimura T, Sugaya M, [Blauvelt A](#), Okochi H, Sato S. Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction. **J Leuk Biol** 2013;94:137-145.
62. Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, [Blauvelt A](#), Shimada S. Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV *ex vivo* infection of Langerhans cells within the epithelium. **J Invest Dermatol** 2013;133:2803-2805.
63. Kimura T, Sugaya M, Oka T, [Blauvelt A](#), Okochi H, Sato S. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. **Oncotarget** 2015;6:18081-18093.
64. Muram TM, Sloan JH, Chain JS, Komocsar WJ, Meiklejohn BI, [Blauvelt A](#), Papp KA, Heffernan MP, Qian YW, Konrad RJ. A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution. **J Invest Dermatol** 2016;136:1513-1515.

65. Reich K, [Blauvelt A](#), Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. **Br J Dermatol** 2017;176:752-758.
66. Loesche MA, Farahi K, Capone K, Fakharzadeh S, [Blauvelt A](#), Callis Duffin K, DePrimo SE, Munoz-Elias EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. **J Invest Dermatol** 2018;138:1973-1981.
67. Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, Muram TM, [Blauvelt A](#). Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. **J Invest Dermatol** 2018;138:2168-2173.
68. Reich K, [Blauvelt A](#), Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. **J Eur Acad Dermatol Venereol** 2019;33:1733-1741.
69. Kimball AB, Kerbusch T, van Aarle F, Kulkarni P, Li Q, [Blauvelt A](#), Papp KA, Reich K, Montgomery D. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. **Br J Dermatol** 2019; Mar 27.
70. Kabasawa M, Fujii H, Sugaya M, Morimura S, Miyagaki T, Okochi H, [Blauvelt A](#), Sato S. Lymphedema attenuates early tissue damage caused by cutaneous vasculitis through decreased production of the neutrophil chemoattractants CXCL1 and CXCL2. **J Dermatol Sci**. Submitted.

Bibliography-Clinical Articles:

71. Ellis CN, Pennes DR, Hermann RC, Blauvelt A, Martel W, Voorhees JJ. Long-term radiographic follow-up after isotretinoin therapy. **J Am Acad Dermatol** 1988;18:1252-1261.
72. Kareti LR, Katlein S, Siew S, Blauvelt A. Angiosarcoma of the adrenal gland. **Arch Pathol Lab Med** 1988;112:1163-1165.
73. Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. **J Am Acad Dermatol** 1991;24:703-705.
74. Blauvelt A, Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. **Arch Dermatol** 1991;127:1159-1166.
75. Blauvelt A, Kerdel FA. Intravenous corticosteroids for systemic mastocytosis (letter). **Arch Dermatol** 1991;127:1586.
76. Nahass GT, Blauvelt A, Leonardi CL, Penneys NS. Basal cell carcinoma of the scrotum: report of three cases and review of the literature. **J Am Acad Dermatol** 1992; 26:574-578.
77. Blauvelt A, Kerdel FA. Cutaneous cryptococcosis mimicking Kaposi's sarcoma as the presenting sign of disseminated disease. **Int J Dermatol** 1992;31:279-280.
78. Blauvelt A, Harris HR, Hogan DJ, Jimenez-Acosta F, Ponce I, Pardo RJ. Porphyria cutanea tarda and human immunodeficiency virus infection. **Int J Dermatol** 1992;31: 474-479.
79. Blauvelt A, Duarte AM, Pruksachatkunakorn C, Leonardi CL, Schachner LA. Human papillomavirus type 6 infection involving cutaneous nongenital sites. **J Am Acad Dermatol** 1992;27:876-879.
80. Nahass GT, Blauvelt A, Penneys NS. Metastases from basal cell carcinoma of the scrotum (letter). **J Am Acad Dermatol** 1992;26:509-10.
81. Blauvelt A, Duarte AM, Schachner LA. Pool palms (letter). **J Am Acad Dermatol** 1992; 27:111.
82. Rotman DA, Blauvelt A, Kerdel FA. Widespread primary cutaneous infection with *Mycobacterium fortuitum*. **Int J Dermatol** 1993;32:512-514.
83. Blauvelt A, Turner ML. Gianotti-Crosti syndrome and human immunodeficiency virus infection. **Arch Dermatol** 1994;130:481-483.

84. Rotman DA, Blauvelt A. Two asymptomatic plaques on the chest of a young woman. **Arch Dermatol** 1994;130:1434-1438.
85. Blauvelt A, Plott RT, Spooner K, Stearn B, Davey RT, Turner ML. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. **Arch Dermatol** 1995;131:360-361.
86. Duarte AM, Perez JL, Blauvelt A, Schachner LA. Ki-1 (CD30) positive anaplastic large cell lymphoma in childhood. **Int Pediatr** 1998;13:232-234.
87. Blauvelt A, Cobb MW, Turner ML. Widespread cutaneous vascular papules associated with peripheral blood eosinophilia and prominent inguinal lymphadenopathy. **J Am Acad Dermatol** 2000;43:698-700.
88. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. **J Am Acad Dermatol** 2002;47:512-518.
89. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, Steinberg SM, Turner ML, Blauvelt A. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. **Arch Dermatol** 2002;138:1341-1346.
90. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML, Blauvelt A. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. **J Am Acad Dermatol** 2004;50:533-540.
91. Ehrlich A, Koch T, Amin B, Liewehr DJ, Steinberg SM, Turner ML, Blauvelt A. Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype. **J Am Acad Dermatol** 2006;54:987-991.e9.
92. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E. Efalizumab for severe atopic dermatitis: a pilot study in adults. **J Am Acad Dermatol** 2007;56:222-227.
93. White KP, Zedek DC, White WL, Simpson EL, Hester E, Morrison L, Lazarova Z, Liu D, Scagliarini A, Kurtz SE, White CR, Yancey KB, Blauvelt A. Orf-induced immunobullous disease: a distinct autoimmune blistering disorder. **J Am Acad Dermatol** 2008;58:49-55.
94. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). **Lancet** 2008;371:1675-1684.

95. Lillis JV, Ansdell VE, Ruben K, Simpson EL, Tumbaga G, Ansdell D, Bremmer S, Kurtz SE, White CR, Blauvelt A, Winthrop KL. Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infections among Satowanese islanders. **Clin Infect Dis** 2009;48:1541-1546.
96. Lee JJ, Mann JA, Blauvelt A. Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. **J Am Acad Dermatol** 2011;64:999-1000.
97. Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. **J Am Acad Dermatol** 2012;67:642-650.
98. Bird JE, Leitenberger JJ, Solomon A, Blauvelt A, Hopkins S. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules. **Dermatol Online J** 2012;18:5.
99. Ku JH, Winthrop KL, Varley CD, Sullivan A, Ehst BD, Blauvelt A, Deodhar AA. Implications for biologic therapy: *Staphylococcus aureus* decolonization of individuals with a history of recurrent skin and soft-tissue infections. **JAMA Dermatol** 2013;149:986-989.
100. Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. **J Drugs Dermatol** 2013;12:874-880.
101. Varley CD, Deodhar AA, Ehst BD, Bakke A, Blauvelt A, Vega R, Yamashita S, Winthrop KL. Persistence of *Staphylococcus aureus* colonization among individuals with immune-mediated inflammatory diseases treated with TNF- α inhibitor therapy. **Rheumatology (Oxford)** 2014;53:332-337.
102. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tying S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. **N Engl J Med** 2014;371:326-338.
103. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. **J Am Acad Dermatol** 2014;71:1176-1182.
104. Garg N, Truong B, Ku JH, Devere TS, Ehst BD, Blauvelt A, Deodhar AA. A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. **Clin Rheumatol** 2015;34:1745-1751.

105. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). **Br J Dermatol** 2015;172:484-493.
106. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. **Lancet** 2015;386:541-551.
107. Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. **J Am Acad Dermatol** 2015;73:400-409.
108. Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpfu S. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. **J Drugs Dermatol** 2015;14:821-833.
109. Truong B, Rich-Garg N, Ehst BD, Deodhar AA, Ku JH, Vakil-Gilani K, Danve A, Blauvelt A. Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. **Clin Cosmet Investig Dermatol** 2015;8:563-569.
110. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. **Lancet** 2016;387:40-52.
111. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. **Br J Dermatol** 2016;175:273-286.
112. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. **J Am Acad Dermatol** 2016;75:77-82.

113. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, [Blauvelt A](#), Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. **J Am Acad Dermatol** 2016;75:83-98.
114. Simpson EL, Gadkari A, Worm M, Soong W, [Blauvelt A](#), Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Sutherland ER, Mastey V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). **J Am Acad Dermatol** 2016;75:506-515.
115. Gordon KB, [Blauvelt A](#), Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. **N Engl J Med** 2016;375:345-356.
116. Gottlieb AB, [Blauvelt A](#), Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. **J Drugs Dermatol** 2016;15:1226-1234.
117. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, [Blauvelt A](#), Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. **N Engl J Med** 2016;375:2335-2348.
118. [Blauvelt A](#), Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. **J Am Acad Dermatol** 2017;76:60-69.
119. [Blauvelt A](#), Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. **J Am Acad Dermatol** 2017;76:405-417.
120. [Blauvelt A](#), Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3). **Am J Clin Dermatol** 2017;18:273-280.

121. Papp KA, [Blauvelt A](#), Bukhalo M, Gooderham M, Krueger J, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. **N Engl J Med** 2017;376:1551-1560.
122. [Blauvelt A](#), de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemeny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. **Lancet** 2017;389:2287-2303.
123. [Blauvelt A](#), Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. **J Eur Acad Dermatol Venereol** 2017;31:1004-1013.
124. [Blauvelt A](#), Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). **J Am Acad Dermatol** 2017;77:372-374.
125. Reich K, Papp KA, [Blauvelt A](#), Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. **Lancet** 2017;390:276-288.
126. [Blauvelt A](#), Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikai E, Dey D, Mallbris L, Reich K. Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. **Br J Dermatol**. 2017;177:587-590.
127. Leonardi CL, [Blauvelt A](#), Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K. Rapid Improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. **J Eur Acad Dermatol Venereol** 2017;31:1483-1490.
128. [Blauvelt A](#), Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. **Br J Dermatol** 2017;177:879-881.

129. Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, Reich K. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). **J Am Acad Dermatol** 2017;77:855-862.
130. Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tying S. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. **J Eur Acad Dermatol Venereol** 2017;31:1693-1699.
131. Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. **Br J Dermatol** 2017;177:1537-1551.
132. Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Munoz-Elias EJ, Callis Duffin K. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). **Br J Dermatol** 2017;177:1552-1561.
133. Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. **J Am Acad Dermatol** 2018;78:81-89.
134. Shear NH, Paul C, Blauvelt A, Gooderham M, Leonardi C, Reich K, Ohtsuki M, Pangallo B, Xu W, Ball S, Ridenour T, Torisu-Itakura H, Agada N, Mallbris L. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. **J Drugs Dermatol** 2018;17:200-206.
135. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. **Br J Dermatol** 2018;178:132-139.
136. Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG. Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. **J Am Acad Dermatol** 2018;78:741-748.
137. Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). **Br J Dermatol** 2018;178:674-681.

138. Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. **J Dermatolog Treat** 2018;29:220-229.
139. Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P. Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). **Br J Dermatol** 2018;178:1315-1323.
140. Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. **JAMA Dermatol** 2018;154:676-683.
141. Lebwohl M, Blauvelt A, Paul C, Sofen H, Weglowska J, Piguat V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). **J Am Acad Dermatol** 2018;79:266-276.
142. Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. **J Am Acad Dermatol** 2018;79:277-286.
143. Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. **J Am Acad Dermatol** 2018;79:294-301.
144. Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). **J Am Acad Dermatol** 2018;79:302-314.
145. Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years. **J Drugs Dermatol** 2018;17:826-832.
146. Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. **J Eur Acad Dermatol Venereol** 2018;32:1515-1522.

147. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. **Lancet** 2018;392:650-661.
148. Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials. **J Am Assoc Nurse Pract** 2018;30:529-541.
149. Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tying SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. **Br J Dermatol** 2018;179:615-622.
150. Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, Jauch-Lembach J, Balfour A, Leonardi CL. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. **Br J Dermatol** 2018;179:623-631.
151. Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, Smith SR, Wilson DC, Bradshaw M, Estes E, Shanler SD. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). **J Am Acad Dermatol** 2018;79:869-877.
152. Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. **Br J Dermatol** 2018;179:844-852.
153. Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). **Dermatol Ther (Heidelb)** 2018;8:571-579.
154. Blauvelt A, Simpson EL, Tying SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. **J Am Acad Dermatol** 2019;80:158-167.

155. Langley RG, Armstrong AW, Lebwohl MG, [Blauvelt A](#), Hsu S, Tying S, Rastogi S, Pillai R, Israel R. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. **Br J Dermatol** 2019;180:306-314.
156. [Blauvelt A](#), Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Roller R, Gottlieb AB. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. **J Eur Acad Dermatol Venereol** 2019;33:546-552.
157. [Blauvelt A](#), Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R. Efficacy of a once-daily fixed combination halobetasol (0.01%) and tazarotene (0.045%) lotion in the treatment of localized moderate-to-severe plaque psoriasis. **J Drugs Dermatol** 2019;18:297-299.
158. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, [Blauvelt A](#), Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. **Arthritis Res Ther** 2019;21:111-121.
159. Curtis JR, Mariette X, Gaujoux-Viala C, [Blauvelt A](#), Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. **RMD Open** 2019;5:e942-e955.
160. Papp KA, Reich K, [Blauvelt A](#), Kimball AB, Gooderham M, Tying SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. **J Eur Acad Dermatol Venereol** 2019;33:1098-1106.
161. [Blauvelt A](#), Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, Deleuran M, Katoch N, Kawashima M, Shumel B, Chen Z, Rossi AB, Hultsch T, Ardeleanu M. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase 3 clinical trials. **Br J Dermatol** 2019;181:196-197.
162. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, [Blauvelt A](#), Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. **Br J Dermatol** 2019;181:459-473.
163. Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, [Blauvelt A](#). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. **Lancet** 2019;394:831-839.

164. Thaçi D, Puig L, Reich K, Tsai TF, Tying S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. **J Am Acad Dermatol** 2019;81:1405-1409.
165. Blauvelt A, Sofen H, Papp K, Gooderham M, Tying S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. **J Eur Acad Dermatol Venereol** 2019;33:2305-2312.
166. Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenther S, Pillai R, Israel RJ, Jacobson A. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis patients treated with brodalumab for 5 years in a long-term, open-label, phase II study. **Am J Clin Dermatol**;20:863-871.
167. Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ. Comparison of health care costs among patients with psoriasis initiating ixekizumab, secukinumab, or adalimumab. **J Manag Care Spec Pharm** 2019;25:1366-1376.
168. Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. **J Am Acad Dermatol** 2020;82:117-122.
169. Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. **J Dermatolog Treat** 2019; Mar 18.
170. Reich K, Thaçi D, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Warren RB. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. **Br J Dermatol** 2019; Jun 19.
171. Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and non-obese patients with psoriasis: analysis of 2 randomized controlled trials. **Br J Dermatol** 2019; Jul 5.
172. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. **J Am Acad Dermatol** 2019; Jul 30.

173. Papp K, [Blauvelt A](#), Sullivan J, Tada Y, Polzer P, Mallbris L, Zhang L, Hong C. Ixekizumab - an effective and safe treatment for moderate-to-severe plaque psoriasis in patients previously treated with other IL-17 inhibitors: results from IXORA-P. **J Psoriasis Psoriatic Arthritis** 2019; Aug 12.
174. Wollenberg A, Beck LA, [Blauvelt A](#), Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). **Br J Dermatol** 2019; Aug 13.
175. Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, [Blauvelt A](#). Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments, and switching from etanercept: results from phase 3 studies. **Br J Dermatol** 2019; Sep 5.
176. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, [Blauvelt A](#), Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. **JAMA Dermatol** 2019; Nov 6.
177. [Blauvelt A](#), Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ. Comparison of real-world treatment patterns among psoriasis patients prescribed ixekizumab or secukinumab. **J Am Acad Dermatol** 2019; Nov 8.
178. Armstrong AW, [Blauvelt A](#), Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A. Defining drug-free remission of skin disease in patients with plaque psoriasis. **Br J Dermatol** 2019; Nov 9.
179. Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, Papp K, Griffiths CEM, [Blauvelt A](#), Reich K, Gooderham M, Terui T, Renda L, Agada N, Xu W, Gallo G, Lebwohl MG. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. **Dermatol Ther (Heidelb)** 2019; Nov 20.
180. Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, [Blauvelt A](#). Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. **J Am Acad Dermatol** 2019; Dec 3.

181. Paller AS, Bansal A, Simpson EL, Boguniewicz M, [Blauvelt A](#), Siegfried EC, Guttman-Yassky E, Hultsch T, Chen Z, Mina-Osorio P, Lu Y, Rossi AB, He X, Kamal M, Graham NMH, Pirozzi G, Ruddy M, Eckert L, Gadkari A. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. **Am J Clin Dermatol** 2019; Dec 10.
182. [Blauvelt A](#), Papp KA, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J. A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial. **Br J Dermatol** 2019; in press.
183. Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, [Blauvelt A](#). Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. **J Am Acad Dermatol** 2019; in press.
184. [Blauvelt A](#), Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Amato D, Zhu B, Murage MJ. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. **J Drugs Dermatol**. Submitted.
185. Golbari NM, van der Walt JM, [Blauvelt A](#), Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds do not correspond to patient impact. **J Am Acad Dermatol**. Submitted.
186. Gelfand JM, Shin DB, Callis Duffin K, Armstrong AW, [Blauvelt A](#), Tying SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Prasad Sankar R, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Werner TJ, Alavi A, Mehta NN. Aortic vascular inflammation in patients with moderate-to-severe plaque psoriasis treated with secukinumab versus placebo (VIP-S). **J Invest Dermatol**. Submitted.
187. [Blauvelt A](#), Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, Brock F, Arendt C, Boehnlein M, Lebwohl M, Reich K. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase 3, randomised, placebo-controlled studies. **Br J Dermatol**. Submitted.
188. Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaci D, [Blauvelt A](#), Worm M, Corren J, Soong W, Lio P, Chen Q, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Staudinger HW, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab improves asthma and sinonasal outcomes in adults with moderate-to-severe atopic dermatitis. **J Allergy Clin Immunol**. Submitted.

189. Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy versus treatment withdrawal in moderate-to-severe plaque psoriasis (IMMhance): a phase 3 randomized clinical trial. **JAMA Dermatol**. Submitted.
190. Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson E. Efficacy and safety of lebrikizumab, a high-affinity IL-13 inhibitor, in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. **JAMA Dermatol**. Submitted.
191. van de Kerkhof PCM, Reich K, Leonardi CL, Blauvelt A, Mehta NN, Tsai TF, You R, Guana A, Milutinovic M, Papanastasiou P, Griffiths CEM. Secukinumab long-term safety: analysis from 19 psoriasis clinical trials. In preparation.
192. Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate-to-severe plaque psoriasis: 52-week results from a double-blinded phase 3b trial (CLARITY). In preparation.
193. Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM. Bimekizumab for patients with moderate-to-severe psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study. In preparation.
194. Blauvelt A, Leonardi CL, Gaylis N, Jauch Lembach J, Haliduola H, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P. Treatment with SDZ-ADL, an adalimumab biosimilar, improves quality of life in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: results from two Phase III studies (ADMYRA and ADACCESS). In preparation.
195. Bykerk VP, Blauvelt A, Curtis JR, Gaujoux-Viala C, Kvien TK, Winthrop K, Popova C, Mariette X, Haraoui B. Influence of disease indication, body mass index, and systemic corticosteroid use on the safety profile of certolizumab pegol. In preparation.
196. Beck LA, Gelfand JM, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in open-label study of adults with moderate-to-severe atopic dermatitis. In preparation.
197. Gordon K, Warren RB, Gottlieb AB, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2). In preparation.

198. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork M, Peris K, Abildgaard Steffensen L, Bang B, Kuznetsova A, Nedergaard Jensen T, Østerdal ML, Simpson E. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomised, double-blinded, placebo-controlled, Phase 3 trials (ECZTRA 1 and ECZTRA 2). In preparation.

Bibliography-Reviews, Book Chapters:

199. Blauvelt A, Katz SI. The skin as target, vector, and effector organ in human immunodeficiency virus disease. **J Invest Dermatol** 1995;105:122S-126S.
200. Blauvelt A. Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. **Arch Dermatol** 1996;132:1503-1504.
201. Blauvelt A. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. **Am J Med** 1997;102:16-20.
202. Majors MJ, Berger TG, Blauvelt A, Smith KJ, Turner ML, Cruz PD. HIV-related eosinophilic folliculitis: a panel discussion. **Sem Cutan Med Surg** 1997;16:219-223.
203. Zoetewij JP, Blauvelt A. HIV-dendritic cell interactions promote efficient viral infection of T cells. **J Biomed Sci** 1998;5:253-259.
204. Blauvelt A. Langerhans Cells. In: **Encyclopedia of Immunology, Second Edition**. Delves PJ, Roitt IM, Eds. Academic Press Ltd., London. 1998, 1528-1532.
205. Blauvelt A. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. **Adv Dermatol** 1999;14:167-207.
206. Blauvelt A. Mucocutaneous Manifestations of the Non-HIV-Infected Immunosuppressed Host. In: **Fitzpatrick's Dermatology in General Medicine, Fifth Edition**. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, Eds. McGraw-Hill, Inc., New York. 1999, 1434-1447.
207. Blauvelt A. Cutaneous Diseases. In: **Handbook of Pediatric HIV Care, First Edition**. Zeichner SL, Read JS, Eds. Lippincott Williams & Wilkens, Philadelphia. 1999, 321-335.
208. Blauvelt A. Skin diseases associated with human herpesvirus 6, 7, and 8 infection. **J Invest Dermatol Symp Proc** 2001;6:197-202.
209. Rubenstein DS, Blauvelt A, Chen SC, Darling TN. The future of academic dermatology in the United States: report on the resident retreat for future physician-scientists, June 15-17, 2001. **J Am Acad Dermatol** 2002;47:300-303.
210. Blauvelt A. In "that" issue. **J Invest Dermatol** 2002;119:1.
211. Piguet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. **J Invest Dermatol** 2002;119:365-369.

212. Blauvelt A, Hwang ST, Udey MC. Allergic and immunologic diseases of the skin. **J Allergy Clin Immunol** 2003;111:560-570.
213. Toro JR, Sanchez S, Turiansky G, Blauvelt A. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. **Dermatol Clin** 2003;21:301-309.
214. Blauvelt A. Mucocutaneous Manifestations of the Non-HIV-Infected Immunosuppressed Host. In: **Fitzpatrick's Dermatology in General Medicine, Sixth Edition**. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Eds. McGraw-Hill, Inc., New York. 2003, 1152-1164.
215. Blauvelt A. In this issue. **J Invest Dermatol** 2003;121:vi.
216. Blauvelt A, Bernhard J. Rapid publication for selected JAAD articles. **J Am Acad Dermatol** 2004;50:299-300.
217. Blauvelt A. Kaposi's sarcoma-associated herpesvirus. **Yale University/Fujisawa Healthcare, Inc. Lectureship Series in Dermatology** 2004;10:1-24.
218. Blauvelt A. In this issue-full court press on psoriasis. **J Invest Dermatol** 2004;123:vii-viii.
219. Blauvelt A. Cutaneous Diseases. In: **Textbook of Pediatric HIV Care**. Zeichner SL, Read JS, Eds. Cambridge University Press, Cambridge. 2005, 413-430.
220. Kawamura T, Kurtz SE, Blauvelt A, Shimada S. The role of Langerhans cells in sexual transmission of HIV-1. **J Dermatol Sci** 2005;40:147-155.
221. Blauvelt A. Cutaneous Diseases. In: **Handbook of Pediatric HIV Care, Second Edition**. Zeichner SL, Read JS, Eds. Cambridge University Press, Cambridge. 2006, 473-502.
222. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF- β 1. **Expert Rev Dermatol** 2007;2:69-78.
223. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. **Curr Rheumatol Rep** 2007;9:461-467.
224. Kauls L, Blauvelt A. Skin Disease in Acute and Chronic Immunosuppression. In: **Fitzpatrick's Dermatology in General Medicine, Seventh Edition**. Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Eds. The McGraw-Hill Companies, Inc., New York. 2008, 267-278.

225. Blauvelt A. Pityriasis Rosea. In: **Fitzpatrick's Dermatology in General Medicine, Seventh Edition**. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Eds. The McGraw-Hill Companies, Inc., New York. 2008, 362-366.
226. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. **J Invest Dermatol** 2008;128:1064-1067.
227. Blauvelt A. HIV Disease and AIDS. In: **Clinical and Basic Immunodermatology**. Gaspari AA, Tying SK, Eds. Springer, London. 2008, 323-334.
228. Blauvelt A, Bickenbach JR, Kulesz-Martin MF, Bowcock AM. Montagna Symposium 2008: the biologic basis of psoriasis. **J Invest Dermatol** 2009;129:259-260.
229. Blauvelt A. Ustekinumab and ABT-874. In: **Moderate-to-Severe Psoriasis, Third Edition**. Koo JYM, Lee CS, Lebwohl MG, Weinstein GD, Gottlieb A, Eds. Informa Healthcare, New York. 2009, 347-364.
230. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. **J Am Acad Dermatol** 2010;63:1058-1069.
231. Pugliese DJ, Gottlieb AB, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A, Van Voorhees AS. Treatment of psoriasis in the setting of excessive alcohol intake: from the Medical Board of the National Psoriasis Foundation. **Psoriasis Forum** 2011;17:119-130.
232. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr. Consensus guidelines for the management of plaque psoriasis. **Arch Dermatol** 2012;148:95-102.
233. Ehst BD, Blauvelt A. Skin Disease in Acute and Chronic Immunosuppression. In: **Fitzpatrick's Dermatology in General Medicine, Eighth Edition**. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, Eds. The McGraw-Hill Companies, Inc., New York. 2012, 330-344.
234. Blauvelt A. Pityriasis Rosea. In: **Fitzpatrick's Dermatology in General Medicine, Eighth Edition**. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, Eds. The McGraw-Hill Companies, Inc., New York. 2012, 458-463.
235. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate**. 2012, online.
236. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate**. 2013, online.

237. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: proceedings from the 2013 MauiDerm meeting. **J Clin Aesthet Dermatol** 2013;6:S2-S20.
238. Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. **J Am Acad Dermatol** 2014;70:168-177.
239. Blauvelt A. Ustekinumab. In: **Moderate to Severe Psoriasis, Fourth Edition**. Levin E, Leon A, Wu JJ, Gottlieb AB, Koo JYM, Eds. CRC Press, Boca Raton. 2014, 217-230.
240. Bhatia N, Blauvelt A, Brown M, High W, Leonardi CT, Rosen T, Stein Gold L, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: proceedings from the 2014 MauiDerm Meeting. **J Clin Aesthet Dermatol** 2014;7:S5-S22.
241. Blauvelt A, Lebwohl M, Bissonnette R. Interleukin-23/interleukin-17A dysfunction phenotypes inform possible clinical effects from anti-interleukin-17A therapies. **J Invest Dermatol** 2015;135:1946-1953.
242. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate**. 2015, online.
243. Blauvelt A, Armstrong AW, Krueger GG. Essential truths for the care and management of moderate-to-severe psoriasis. **J Drugs Dermatol** 2015;14:805-812.
244. Blauvelt A, Cohen AD, Puig L, Vender R, van der Walt J, Wu JJ. Biosimilars for psoriasis: pre-clinical analytical assessment to determine similarity. **Br J Dermatol** 2016;174:282-286.
245. Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to-severe plaque psoriasis. **Expert Opin Biol Ther** 2016;16:255-263.
246. Blauvelt A. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. **PracticeUpdate**. <http://www.practiceupdate.com/content/tnf-inhibitors-improve-insulin-sensitivity-in-psoriasis-patients-with-type-2-diabetes/37580/65/4/1>. April 27, 2016.
247. Blauvelt A. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. **PracticeUpdate**. <http://www.practiceupdate.com/content/ixekizumab-in-moderate-to-severe-plaque-psoriasis/40425/65/4/1>. July 12, 2016.
248. Armstrong AW, Bukhalo M, Blauvelt A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis. **Am J Clin Dermatol** 2016;17:329-336.

249. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. **Expert Opin Drug Saf** 2016;15:1413-1420.
250. Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR. A boxed warning for inadequate psoriasis treatment. **Cutis** 2016;98:206-207.
251. Blauvelt A. Head-to-head comparison of secukinumab versus ustekinumab for psoriasis. **PracticeUpdate**. <http://www.practiceupdate.com/content/secukinumab-is-superior-to-ustekinumab-in-clearing-moderate-to-severe-plaque-psoriasis-up-to-1year/44533/65/4/1>. October 18, 2016.
252. Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E. Updates on psoriasis and cutaneous oncology: proceedings from the 2016 MauiDerm Meeting. **J Clin Aesthet Dermatol** 2016;9:S5-S29.
253. Blauvelt A, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, Skov L, Zachariae C, Young H, Prens E, Cohen A, van der Walt J, Wu JJ. Biosimilars for psoriasis: clinical studies to determine similarity. **Br J Dermatol** 2017;177:23-33.
254. Blauvelt A. IL-6 differs from TNF- α : unpredicted clinical effects caused by IL-6 blockade in psoriasis. **J Invest Dermatol** 2017;137:541-542.
255. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. UpToDate. 2017, online.
256. Cohen AD, Wu JJ, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, de la Cruz C, Skov L, Zachariae C, Young HS, Foley P, van der Walt JM, Naldi L, Prens EP, Blauvelt A. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. **Br J Dermatol** 2017;177:1495-1502.
257. Blauvelt A. Dual inhibition of IL-12/IL-23 and selective inhibition of IL-23 in psoriasis. In: **Biologic and Systemic Agents in Dermatology**. Yamauchi PS, Ed. Springer, Cham, Switzerland. 2018, 123-131.
258. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. **Drugs** 2018;78:463-478.
259. Siegfried EC, Jaworski JC, Eichenfield LF, Paller A, Hebert AA, Simpson EL, Altman E, Arena C, Blauvelt A, Block J, Boguniewicz M, Chen S, Cordero K, Hanna D, Horii K, Hultsch T, Lee J, Leung DY, Lio P, Milner J, Omachi T, Schneider C, Schneider L, Sidbury R, Smith T, Sugarman J, Taha S, Tofte S, Tollefson M, Tom WL, West DP, Whitney L, Zane L. Developing drugs for treatment of atopic dermatitis in children (≥ 3 months to < 18 years of age): draft guidance for industry. **Pediatr Dermatol** 2018;35:303-322.

260. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Authors' reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes." **Drugs** 2018;78:853-855.
261. Blauvelt A. Vaccination in the setting of dupilumab therapy for atopic dermatitis. **PracticeUpdate**. <http://www.practiceupdate.com/content/dupilumab-does-not-affect-correlates-of-vaccine-induced-immunity/72266/65/4/1>. August 30, 2018.
262. Strober BE, Gelfand JM, Blauvelt A, Kavanaugh A, Leonardi CL, Stein Gold L. Updates in psoriasis management: proceedings from the 2018 MauiDerm meeting. **J Clin Aesthet Dermatol** 2018;11:S6-S23.
263. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. **Clin Rev Allergy Immunol** 2018;55:379-390.
264. Blauvelt A, Shumel B. Response to critical appraisal of LIBERTY AD CHRONOS. **Br J Dermatol** 2018;179:1423.
265. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate**. 2019, online.
266. Blauvelt A. Predicting clinical responses to ustekinumab: progress toward a future of personalized medicine. **JAMA Dermatol** 2019;155:1227-1228.
267. Blauvelt A, Chiricozzi A, Ehst BD. Bimekizumab. **Curr Derm Rep** 2019; in press.
268. Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. **J Drugs Dermatol**. Submitted.

National/International Presentations:

1. Use of contaminated L-tryptophan is associated with eosinophilic fasciitis and generalized morphea. Residents and Fellows Symposium, American Academy of Dermatology. Atlanta, GA. December 1990.
2. Zhu WY, Blauvelt A, Goldstein BA, Leonardi CL, Penneys NS. Detection of human papillomavirus DNA in condyloma acuminata treated in vitro with liquid nitrogen, trichloroacetic acid, and podophyllin (poster). Society for Investigative Dermatology. Seattle, WA. May 1991.
3. Widespread primary cutaneous infection with *Mycobacterium fortuitum*. Gross and Microscopic Dermatology, American Academy of Dermatology. Dallas, TX. December 1991.
4. Blauvelt A, Iriondo M. Large surgical wounds heal naturally with acceptable cosmetic results (poster). American Academy of Dermatology. Dallas, TX. December 1991.
5. Duarte AM, Blauvelt A, Schachner LA. Ki-1 positive large cell lymphoma in childhood (poster). American Academy of Dermatology. Washington, DC. December 1993.
6. Blauvelt A, Clerici M, Lucey DR, Yarchoan R, Walker R, Shearer GM, Katz SI. Antigen presentation by epidermal Langerhans cells in HIV-infected individuals (poster). The First National Conference on Human Retroviruses and Related Infections. Washington, DC. December 1993.
7. Antigen presentation by epidermal Langerhans cells in HIV-infected individuals is normal (invited speaker). Society for Investigative Dermatology. Baltimore, MD. April 1994.
8. Immunologic assessment of skin disease in AIDS (invited speaker). Triservices Dermatology Meeting. Bethesda, MD. May 1994.
9. The skin as target, vector, and effector organ in HIV disease (invited speaker). 43rd Annual Montagna Symposium on the Biology of the Skin. Snowmass, CO. August 1994.
10. Blauvelt A, Chougnet C, Shearer GM, Katz SI. T cell responses to protein antigens presented by Langerhans cells in HIV-discordant identical twins: modulation of responses by anti-IL-10 antibodies and IL-12 (invited speaker). Keystone Symposium on Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes. Taos, NM. March 1995.
11. Blauvelt A, Chougnet C, Shearer GM, Katz SI. T cell responses to protein antigens presented by Langerhans cells in HIV-discordant identical twins: modulation of responses by anti-IL-10 antibodies and IL-12 (poster). Interleukin-12 in Infection: Prospects for Prophylactic and Therapeutic Intervention. Bethesda, MD. May 1995.
12. T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins: modulation of responses by anti-IL-10 antibodies and IL-12 (invited speaker). Society for Investigative Dermatology. Chicago, IL. May 1995.
13. Blauvelt A, Saville MW, Asada H, Klaus-Kovtun V, Yarchoan R, Katz SI. Productive infection of cultured dendritic cells by HIV and their ability to capture virus are mediated through separate pathways (poster). Annual Meeting of the Laboratory of Tumor Cell Biology. Bethesda, MD. August 1995.
14. The role of skin dendritic cells in initial HIV infection (invited speaker). Centers for Disease Control workshop on HIV Post-Exposure Management of Health Care Workers. Atlanta, GA. March 1996.

15. Productive infection of Langerhans cell-like dendritic cells by HIV and their ability to capture virus are mediated through separate pathways (invited speaker). Society for Investigative Dermatology. Washington, DC. May 1996.
16. The role of Langerhans cells in the immunopathogenesis of HIV disease (invited speaker). The 1st Forum of the Japanese Society for Investigative Dermatology. Tokyo. March 1997.
17. The role of human herpesvirus type 8 in the pathogenesis of Kaposi's sarcoma (invited speaker). The 1st Forum of the Japanese Society for Investigative Dermatology. Tokyo. March 1997.
18. Blauvelt A, Sei S, Cook PM, Schulz TF, Jeang KT. Human herpesvirus 8 infection occurs following adolescence in the United States (poster). Keystone Symposium on AIDS Pathogenesis. Keystone, CO. April 1997.
19. Primary human herpesvirus type 8 infection occurs following adolescence in the United States (invited speaker). Society for Investigative Dermatology. Washington, DC. April 1997.
20. Expression of CCR-5, but not CXCR-4, on freshly isolated Langerhans cells correlates with restricted transmission of macrophage-tropic HIV (invited speaker). Society for Investigative Dermatology. Washington, DC. April 1997.
21. Primary human herpesvirus type 8 infection occurs following adolescence in the United States (invited speaker). National AIDS Malignancy Conference. Bethesda, MD. April 1997.
22. Surface expression of CCR-5, but not CXCR-4, on freshly isolated Langerhans cells correlates with restricted transmission of macrophage-tropic HIV (invited speaker). 5th International Workshop on Langerhans Cells. Salzburg, Austria. September 1997.
23. Zoetewij JP, Zaitseva M, Lapham C, Manischewitz J, Klaus-Kovtun V, Golding H, Blauvelt A. Cytokine regulation of CCR-5, CXCR-4 and CD4 on epidermal Langerhans cells (poster). Symposium on HIV-1 Infection, Mucosal Immunity & Pathogenesis. Bethesda, MD. September 1997.
24. Asada H, Klaus-Kovtun V, Golding H, Katz SI, Blauvelt A. Human herpesvirus 6 infects dendritic cells and suppresses HIV replication in co-infection studies (poster). Annual Meeting of the Institute of Human Virology. Baltimore, MD. September 1997.
25. Langerhans cells as the initial target cells for HIV following sexual exposure to virus (invited speaker). AIDS Symposium, American Academy of Dermatology. Orlando, FL. February 1998.
26. Immune dysregulation in HIV infection (invited speaker). Immunology: From the Bench to the Bedside, American Academy of Dermatology. Orlando, FL. March 1998.
27. How human herpesvirus 8 may cause Kaposi's sarcoma. Focus session, American Academy of Dermatology. Orlando, FL. March 1998.
28. The role of HIV in the pathogenesis of AIDS-associated Kaposi's sarcoma (invited speaker). Symposium on Kaposi's Sarcoma: Recent Advances in Virology and Treatment. Cleveland, OH. March 1998.
29. Type 2 cytokines upregulate and type 1 cytokines downregulate expression and function the HIV coreceptor CXCR4 in human Langerhans cells (invited speaker). Symposium on Cutaneous Immunology. Mainz, Germany. May 1998.

30. Human herpesvirus 6 infects dendritic cells and suppresses HIV replication in co-infected cultures (invited speaker). International Investigative Dermatology. Cologne, Germany. May 1998.
31. Zoetewij JP, Golding H, Blauvelt A. Cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells (poster). Annual Meeting of the Institute of Human Virology. Baltimore, MD. August 1998.
32. Chougnet C, Sharpe S, Landay AL, Smith K, Kessler HA, Blauvelt A, Shearer GM. Monocyte-derived dendritic cells from HIV+ patients produce normal amounts of IL-12 and IL-10 (poster). Annual Meeting of the Institute of Human Virology. Baltimore, MD. August 1998.
33. Blauvelt A, Glushakova S, Margolis LB. HIV-infected Langerhans cells transmit virus to lymphoid tissue in a novel model of primary HIV infection (poster). 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 1999.
34. HIV and the immune system (invited speaker). Immunology course, American Academy of Dermatology. New Orleans, LA. March 1999.
35. How human herpesvirus 8 may cause Kaposi's sarcoma. Focus session, American Academy of Dermatology. New Orleans, LA. March 1999.
36. Human herpesviruses 7 and 8: links to pityriasis rosea and Kaposi's sarcoma (invited speaker). 76th Atlantic Dermatological Conference. Washington, DC. April 1999.
37. HIV-1 primary isolate infection of immature Langerhans cells within epithelial sheets: a novel model to study early events of primary HIV infection (invited speaker). Society for Investigative Dermatology. Chicago, IL. May 1999.
38. Zoetewij JP, Eyes ST, Orenstein JM, Kawamura T, Wu L, Chandran B, Forghani B, Blauvelt A. Identification and rapid quantification of lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesviral agents (poster). Society for Investigative Dermatology. Chicago, IL. May 1999.
39. Blauvelt A, Glushakova S, Margolis LB. HIV-infected human epidermal Langerhans cells migrate into and infect human lymphoid tissue (poster). Society for Investigative Dermatology. Chicago, IL. May 1999.
40. Kawamura T, Qalbani M, Orenstein JM, Blauvelt A. Human monocyte-derived dendritic cells propagated in the presence of GM-CSF, IL-4, and TGF β 1 morphologically, phenotypically, and functionally resemble resident epidermal Langerhans cells (poster). Society for Investigative Dermatology. Chicago, IL. May 1999.
41. Zoetewij JP, Eyes ST, Kawamura T, Cohen SS, Wu L, Chandran B, Forghani B, Blauvelt A. Characterization and rapid quantification of lytic human herpesvirus 8 infection in single cells by flow cytometric analysis (poster). 3rd National AIDS Malignancy Conference. Bethesda, MD. May 1999.
42. Cohen SS, Kawamura T, Zoetewij JP, Aquilino EA, Qalbani M, Orenstein JM, Neurath AR, Blauvelt A. HIV-1 primary isolate infection of immature Langerhans cells within epithelial tissue explants: a novel model to study early biologic events involved in sexual transmission of HIV-1 (poster). Annual Meeting of the Institute of Human Virology. Baltimore, MD. August 1999.
43. Corticosteroids and cyclosporine directly stimulate human herpesvirus 8 reactivation in latently infected cells: implications for development of Kaposi's sarcoma (invited speaker). 2nd International Workshop on Kaposi's Sarcoma Associated Herpesvirus and Related Agents. Oxford, England. September 1999.

44. HIV primary isolate infection of immature Langerhans cells within epithelial tissue explants: a novel model to study early biologic events involved in sexual transmission of HIV (invited speaker). 6th International Workshop on Langerhans Cells. New York, NY. October 1999.
45. Kawamura T, Qalbani M, Orenstein JM, Blauvelt A. Human monocyte-derived dendritic cells propagated in the presence of GM-CSF, IL-4, and TGF β 1 morphologically, phenotypically, and functionally resemble resident epidermal Langerhans cells (poster). 6th International Workshop on Langerhans Cells. New York, NY. October 1999.
46. HIV and the immune system (invited speaker). Immunology course, American Academy of Dermatology. San Francisco, CA. March 2000.
47. How human herpesvirus 8 may cause Kaposi's sarcoma. Focus session, American Academy of Dermatology. San Francisco, CA. March 2000.
48. The role of HHV-8 in KS (invited speaker). AIDS and STD Symposium, American Academy of Dermatology. San Francisco, CA. March 2000.
49. *Ex vivo* HIV-1 infection of human immature Langerhans cells within epithelial tissue explants: a novel model for sexual transmission of HIV-1 (invited speaker). Microbicides 2000. Washington, DC. March 2000.
50. Epithelial and mucosal explant models (invited speaker). Biology of HIV Transmission Think Tank. Warrenton, VA. April 2000.
51. Distinct calcineurin- and protein kinase C-mediated signal transduction pathways are involved in reactivation of Kaposi's sarcoma-associated herpesvirus in latently infected cells (invited speaker). Society for Investigative Dermatology. Chicago, IL. May 2000.
52. Pathogenesis of skin diseases associated with human herpesviruses 6, 7, and 8 (invited speaker). 49th Annual Montagna Symposium on the Biology of the Skin. Snowmass, CO. August 2000.
53. Skin disease in HIV-infected individuals (invited speaker). Georgia Department of Corrections Annual Meeting. Macon, GA. February 2001.
54. The role of Langerhans cells in the sexual transmission of HIV (invited speaker). AIDS & STD Symposium, American Academy of Dermatology. Washington, DC. March 2001.
55. HIV and the immune system (invited speaker). Immunology course, American Academy of Dermatology. Washington, DC. March 2001.
56. How KSHV may cause Kaposi's sarcoma. Focus session, American Academy of Dermatology. Washington, DC. March 2001.
57. gp120 secreted by HIV-infected dendritic cells suppresses CD4⁺ T cell proliferation and IL-2 production: reversal of immunosuppression by soluble CD4, but not by anti-retroviral drugs (invited speaker). Keystone Symposium on Dendritic Cells: Interfaces with Immunobiology and Medicine. Taos, NM. March 2001.
58. RANTES analogues block R5 HIV-1 infection of Langerhans cells within epithelial tissue explants (poster). Keystone Symposium on Dendritic Cells: Interfaces with Immunobiology and Medicine. Taos, NM. March 2001.
59. T cell dysfunction induced by HIV-infected dendritic cells (invited speaker). Society for Investigative Dermatology. Washington, DC. May 2001.
60. Clinical and immunologic assessment of psoriasis patients in a randomized double-blind placebo-controlled trial using recombinant human interleukin-10 (poster). Society for Investigative Dermatology. Washington, DC. May 2001.

61. Comparative inhibition of R5 HIV infection in epidermal Langerhans cells by novel chemically modified RANTES analogues (poster). Society for Investigative Dermatology. Washington, DC. May 2001.
62. Clinical and immunologic assessment of psoriasis patients in a randomized double-blind placebo-controlled trial using recombinant human interleukin-10 (invited speaker). International Psoriasis Symposium. San Francisco, CA. June 2001.
63. Watanabe T, Atkins AM, Aquilino EA, Blauvelt A. Cloning and genomic characterization of the murine *VEGFR-3* gene and promoter (poster). 4th International Workshop on KSHV and Related Agents. Santa Cruz, CA. August 2001.
64. Chemically modified RANTES analogues block CCR5-mediated HIV infection of Langerhans cells within epithelial tissue explants (invited speaker). 7th International Workshop on Langerhans Cells. Stresa, Italy. September 2001.
65. HIV infection of LC and DC *in vitro* (invited speaker). Antigen Presenting Cells in HIV Pathogenesis and Therapy Think Tank. Warrenton, VA. October 2001.
66. HIV and the immune system (invited speaker). Immunology course, American Academy of Dermatology. New Orleans, LA. February 2002.
67. Topical microbicides to prevent sexual transmission of HIV (invited speaker). AIDS & STD Symposium, American Academy of Dermatology, New Orleans, LA. February 2002.
68. KSHV *LANA* immortalizes primary human umbilical vein endothelial cells (invited speaker). 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda, MD. April 2002.
69. Sugaya M, Watanabe T, Atkins AM, Aquilino EA, Borris DL, Jaffe E, Feigenbaum L, Blauvelt A. Transgenes expressed under the control of the *VEGFR-3* promoter are selectively expressed by lymphatic endothelial cells of transgenic mice (poster). 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda, MD. April 2002.
70. HIV infection of human Langerhans cells in tissue explants (invited speaker). Immune Mechanisms in HIV Disease. Cleveland, OH. May 2002.
71. Histone deacetylase inhibitors reactivate Kaposi's sarcoma-associated herpesvirus (invited plenary speaker). Society for Investigative Dermatology. Los Angeles, CA. May 2002.
72. Role of KSHV in KS pathogenesis (invited speaker). 20th World Congress of Dermatology. Paris, France. July 2002.
73. Topical microbicides to prevent sexual transmission of HIV (invited speaker). 20th World Congress of Dermatology. Paris, France. July 2002.
74. Langerhans cell biology and pathology (invited speaker). Basic Science Course, American Academy of Dermatology summer meeting. New York, NY. August 2002.
75. R5 HIV infection of Langerhans cells within epithelial tissue explants is regulated by compound *CCR5* polymorphisms and is blocked by chemically modified RANTES analogues (poster). 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2003.
76. Immunological responses to pathogens (invited speaker). Immunology course, American Academy of Dermatology. San Francisco, CA. March 2003.

77. Preventing sexual transmission of HIV by topical microbicides (invited speaker). AIDS & STD Symposium, American Academy of Dermatology. San Francisco, CA. March 2003.
78. R5 HIV infection of Langerhans cells within epithelial tissue explants is regulated by compound *CCR5* polymorphisms and is blocked by chemically modified RANTES analogues (poster). Topical Microbicides Development and Evaluation Workshop. Washington, DC. March 2003.
79. Lymphatic dysfunction in Kaposi's sarcoma-associated herpesvirus *k-cyclin* transgenic mice (poster). 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda, MD. April 2003.
80. Lymphatic dysfunction in Kaposi's sarcoma-associated herpesvirus *k-cyclin* transgenic mice (poster). International Investigative Dermatology. Miami Beach, FL. May 2003.
81. Langerhans cell biology (invited speaker). State-of-the-Art Issues in Contact Dermatitis. Hershey, PA. July 2003.
82. Langerhans cell biology and pathology (invited speaker). Basic Science Course, American Academy of Dermatology summer meeting. Chicago, IL. July 2003.
83. Immunological responses to pathogens (invited speaker). Immunology course, American Academy of Dermatology. Washington, DC. February 2004.
84. Langerhans cells as initial targets for HIV (invited speaker). AIDS & STD Symposium, American Academy of Dermatology. Washington, DC. February 2004.
85. The role of Langerhans cells in HIV pathogenesis (invited speaker). Society for Investigative Dermatology. Providence, RI. May 2004.
86. Targeted inhibition of CCR5 with PSC-RANTES is sufficient to block intravaginal transmission of SHIV in rhesus macaques (invited speaker). Society for Investigative Dermatology. Providence, RI. May 2004.
87. Langerhans cell biology and pathology (invited speaker). Basic Science Course, American Academy of Dermatology summer meeting. New York, NY. July 2004.
88. Update on Immunotherapy for Cancer (invited speaker). American Academy of Dermatology summer meeting. New York, NY. July 2004.
89. HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4⁺ memory T cells located in Langerhans cell-T cell clusters (invited speaker). 2004 International Meeting of the Institute of Human Virology. Baltimore, MD. November 2004.
90. Immunology update (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2005.
91. Virology update (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2005.
92. HIV disease: 25 years of success & failure (invited speaker). American Academy of Dermatology annual meeting. New Orleans, LA. February 2005.
93. Update on KSHV & Kaposi's sarcoma (invited speaker). American Academy of Dermatology annual meeting. New Orleans, LA. February 2005.
94. CCR5 mediated infection of Langerhans cells (invited speaker). Keystone Symposium on HIV Pathogenesis. Banff, Canada. April 2005.

95. C34, a membrane fusion inhibitor, blocks HIV infection of human Langerhans cells and LC-mediated transfer of virus to T cells (invited speaker). Clinical Scholars Program. Society for Investigative Dermatology. St. Louis, MO. May 2005.
96. C34, a membrane fusion inhibitor, blocks HIV infection of human Langerhans cells and LC-mediated transfer of virus to T cells (invited speaker). Society for Investigative Dermatology. St. Louis, MO. May 2005.
97. How HIV interacts with Langerhans cells (invited speaker). 9th International Workshop on Langerhans Cells. Funchal, Portugal. September 2005.
98. New concepts in the pathogenesis and treatment of psoriasis (invited speaker). Dermatology Foundation Clinical Symposia. Naples, FL. January 2006.
99. Skin disease and treatment in HIV-infected individuals receiving HAART (invited speaker). Dermatology Foundation Clinical Symposia. Naples, FL. January 2006.
100. Psoriasis: a model of an immunologic disease (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2006.
101. Infectious diseases of the skin 2006 (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2006.
102. Careers in academic dermatology (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2006.
103. HIV skin disease - current issues (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2006.
104. Efalizumab causes marked increases in the percentages of circulating T cells expressing cutaneous lymphocyte antigen in patients with atopic dermatitis (poster). Society for Investigative Dermatology. Philadelphia, PA. May 2006.
105. A novel orf-induced subepidermal immunobullous mucocutaneous disease (poster). Society for Investigative Dermatology. Philadelphia, PA. May 2006.
106. Psoriatic arthritis 101: learning the basics (invited speaker). National Psoriasis Foundation 2006 National Conference. Portland, OR. August 2006.
107. Drugs in development: the research pipeline (invited speaker). National Psoriasis Foundation 2006 National Conference. Portland, OR. August 2006.
108. Current concepts in the immunology of cutaneous diseases (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2007.
109. New drugs for psoriasis on the horizon (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2007.
110. Clinical update on HIV and herpesviruses (invited speaker). Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2007.
111. Careers in academic dermatology (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. February 2007.
112. Practical aspects of treating individuals with psoriasis (invited speaker). Caremark National Pharmacy & Therapeutics Committee Meeting. Chicago, IL. February 2007.
113. The innovative 90's (invited speaker). Celebrating 50 years of excellence in dermatology and cutaneous surgery at the University of Miami. Miami Beach, FL. March 2007.
114. Topical microbicides to block sexual transmission of HIV (invited speaker). Celebrating 50 years of excellence in dermatology and cutaneous surgery at the University of Miami. Miami Beach, FL. March 2007.

115. Targeting the IL-23/IL-17 inflammatory pathway in humans: lessons learned from psoriasis (invited speaker). American Uveitis Society annual meeting. Ft. Lauderdale, FL. May 2007.
116. Psoriasis as a Th17 disease? American Dermatological Association annual meeting. Beaver Creek, CO. August 2007.
117. Th17 cells are present in psoriasis lesional skin and produce cytokines that stimulate CCL20 production by keratinocytes. Montagna Symposium on the Biology of Skin. Gleneden Beach, OR. October 2007.
118. *Acad*, the academia gene (invited speaker). American Academy of Dermatology annual meeting. San Antonio, TX. February 2008.
119. Emerging trends in psoriasis (invited speaker). American Academy of Dermatology annual meeting. San Antonio, TX. February 2008.
120. Update on topical microbicides to prevent sexual transmission of HIV (invited speaker). Maui Derm 08: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2008.
121. Evolving concepts in the immunology of cutaneous diseases (invited speaker). Maui Derm 08: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2008.
122. Clinical study data on new biologics for psoriasis (invited speaker). MauiDerm 08: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2008.
123. Th17 cells present in psoriasis produce cytokines that promote CCR6-CCL20 mediated chemotaxis of additional Th17 cells into skin (poster). International Investigative Dermatology meeting. Kyoto, Japan. May 2008.
124. Psoriasis-like disease in *K5.hTGF- β 1* transgenic mice is not dependent upon the IL-23/Th17 inflammatory pathway (poster). International Investigative Dermatology meeting. Kyoto, Japan. May 2008.
125. Identification and quantification of Th17 cells in psoriasis. Montagna Symposium on the Biology of Skin. Gleneden Beach, OR. October 2008.
126. The science of psoriasis. National Psoriasis Foundation 10th Annual Chief Resident's Meeting on Psoriasis and Psoriatic Arthritis. Chicago, IL. November 2008.
127. Immunology update 2009: more evidence for IL-23 as a "master cytokine" and critical target in psoriasis (invited speaker). Maui Derm 09: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2009.
128. Infections associated with TNF- α blockers: fact and fiction (invited speaker). Maui Derm 09: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2009.
129. IL-23 as a master cytokine and critical target in psoriasis (invited speaker). Dermatology Nurses' Association annual meeting. San Francisco, CA. March 2009.
130. *Acad*, the academia gene (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2009.
131. Genetics and immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2009.
132. Immunodermatology update (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2009.
133. Immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2009.
134. IL-23 as a critical target for future psoriasis therapy (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2009.

135. IL-23 as a master cytokine and critical target in psoriasis (invited speaker). Dermatology Update annual meeting. Montreal, Canada. March 2009.
136. Update on ustekinumab (invited speaker). Dermatology Update annual meeting. Montreal, Canada. March 2009.
137. Psoriasis: cutting edge advances for an ancient disease (invited speaker). National Psoriasis Foundation webcast. Portland, OR. March 2009.
138. Th17 cells in skin immunity and disease (invited speaker). Society for Investigative Dermatology annual meeting. Montreal, Canada. May 2009.
139. MAPK-dependent CCL21 expression by lymphatic endothelial cells (poster). Society for Investigative Dermatology annual meeting. Montreal, Canada. May 2009.
140. Increased IL-23 expression, but not IL-12, in individuals with hyperkeratotic hand dermatitis or palmoplantar psoriasis (poster). Society for Investigative Dermatology annual meeting. Montreal, Canada. May 2009.
141. NF- κ B- and STAT3-dependent cytokine production by circulating CCR6+CD4+ Th17 cells is increased in psoriasis, and decreases with effective therapy (poster). Society for Investigative Dermatology annual meeting. Montreal, Canada. May 2009.
142. Psoriasis as a systemic inflammatory disease: increases in circulating Th17, Th1, Th17/Th1, and Th22 cells (poster). 2nd World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. June 2009.
143. In vivo measurements of epidermal thickness by reflectance mode confocal microscopy to assess cellular proliferation induced by topical agents (poster). Biophotonics '09. Ven, Sweden. June 2009.
144. Prevalence of *Staphylococcus aureus* colonization among those using biologic therapy (poster). American College of Rheumatology annual scientific meeting. Philadelphia, PA. October 2009.
145. The science that underlies the development and use of ustekinumab (invited speaker). Maui Derm 10: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2010.
146. Psoriasis in women and children (invited speaker). Maui Derm 10: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2010.
147. Infliximab therapy in psoriasis patients previously treated with etanercept: final efficacy and safety results from a multicenter, prospective study (poster). American Academy of Dermatology. Miami, FL. March 2010.
148. Immunodermatology update (invited speaker). American Academy of Dermatology annual meeting. Miami, FL. March 2010.
149. Immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. Miami, FL. March 2010.
150. IL-23-mediated epidermal hyperplasia is dependent on IL-17A in mice (poster). Society for Investigative Dermatology annual meeting. Atlanta, GA. May 2010.
151. IL-23 and Th17 cytokines control cutaneous infection with *Candida albicans* as well as *C. albicans*-induced epidermal hyperplasia (poster). Society for Investigative Dermatology annual meeting. Atlanta, GA. May 2010.
152. Production of LL-37 during herpes simplex virus type 2 infection in human keratinocytes enhances HIV susceptibility in Langerhans cells (poster). Society for Investigative Dermatology annual meeting. Atlanta, GA. May 2010.

153. Role of IL-23 and Th17 cells in the pathogenesis of psoriasis (invited speaker). Clinical Immunology Society annual meeting. Philadelphia, PA. May 2010.
154. Efficacy, safety, and health-related quality of life of infliximab therapy in plaque psoriasis patients previously treated with etanercept: analysis of PSUNRISE study group (poster). Congress of the Psoriasis International Network. Paris, France. July 2010.
155. Dermatologists as gatekeepers for multidisciplinary care of psoriasis (invited speaker). Murdough Family Center for Psoriasis 2nd Annual CME Clinical Symposium. Cleveland, OH. September 2010.
156. Infliximab improves high-impact features of psoriasis in patients with an inadequate response to etanercept: analysis of PSUNRISE results (poster). European Academy of Dermatology and Venereology annual meeting. Gothenburg, Sweden. October 2010.
157. Role of IL-23 and Th17 cells in skin infections and psoriasis. Department of Dermatology Special Lecture. Aarhus University. Aarhus, Denmark. October 2010.
158. Colonization and infection by *Staphylococcus aureus* among those using biologic therapy (poster). American College of Rheumatology annual meeting. Atlanta, GA. October 2010.
159. Immunodermatology (invited speaker). American Academy of Dermatology annual meeting. New Orleans, LA. February 2011.
160. Immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. New Orleans, LA. February 2011.
161. New developments in blockade of the IL-23/IL-17 pathway in psoriasis (invited speaker). American Academy of Dermatology annual meeting. New Orleans, LA. February 2011.
162. ESPRIT: Interim results from a 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis (poster). American Academy of Dermatology annual meeting. New Orleans, LA. February 2011.
163. Cutaneous immunology (invited speaker). Maui Derm 2011: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2011.
164. Psoriasis update 2011 (invited speaker). Maui Derm 2011: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2011.
165. Infectious disease update 2011 (invited speaker). Maui Derm 2011: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2011.
166. The immunological basis of common dermatologic diseases (invited speaker). Dermatology Nurses' Association annual meeting. San Diego, CA. March 2011.
167. Viruses and skin diseases (invited speaker). Dermatology Nurses' Association annual meeting. San Diego, CA. March 2011.
168. High prevalence of psoriatic arthritis with a significant impact on quality of life in psoriasis patients evaluated at a multidisciplinary center for complex psoriatic disease (poster). Society for Investigative Dermatology annual meeting. Phoenix, AZ. May 2011.
169. *Staphylococcus aureus* colonization does not increase the rate of infection among psoriasis patients using biologic therapy (poster). Society for Investigative Dermatology annual meeting. Phoenix, AZ. May 2011.
170. An orally delivered CCR5 inhibitor, Maraviroc, prevents HIV-1 acquisition in Langerhans cells and transmission to CD4+ T cells (poster). Society for Investigative Dermatology annual meeting. Phoenix, AZ. May 2011.

171. Higher prevalence of *Staphylococcal aureus* colonization in psoriatic patients may predispose to incident infections (poster). Group for Research and Assessment of Psoriasis and Psoriatic Arthritis annual meeting. Naples, Italy. July 2011.
172. Conflict of interest disclosure: not enough (invited speaker). American Dermatological Association annual meeting (invited speaker). Napa, CA. September 2011.
173. Infections on immunosuppressives (invited speaker). Maui Derm 2012: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2012.
174. Immunology update (invited speaker). Maui Derm 2012: Advances in Cosmetic & Medical Dermatology. Wailea, HI. February 2012.
175. Immunodermatology update (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. March 2012.
176. Immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. March 2012.
177. Practical immunology (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. March 2012.
178. Targeted therapies for psoriasis (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. March 2012.
179. Do we know the cost of dermatologic specialty care? A survey of dermatology providers, residents and patients (poster). Society for Investigative Dermatology annual meeting. Raleigh, NC. May 2012.
180. Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction (poster). Society for Investigative Dermatology annual meeting. Raleigh, NC. May 2012.
181. Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA) (poster). 3rd World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. June 2012.
182. Clinical features of actinic keratoses (invited speaker). Symbio Investigator Meeting. Santa Fe, NM. August 2012.
183. The science behind new therapies for psoriasis (invited speaker). Ricky K. Schachter Lecturer in Psoriasis. University of Toronto. Toronto, Canada. September 2012.
184. Managing complicated cases of psoriasis (invited speaker). Ricky K. Schachter Lecturer in Psoriasis. University of Toronto. Toronto, Canada. September 2012.
185. Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis (poster). American College of Rheumatology annual meeting. Washington, DC. November 2012.
186. Immunodermatology (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Wailea, HI. January 2013.
187. Infections: year in review (invited speaker). Maui Derm 2013: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2013.
188. Immunodermatology: year in review (invited speaker). Maui Derm 2013: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2013.
189. Evolving concepts in understanding the role of cytokines in the pathogenesis of psoriasis (invited speaker). American Academy of Dermatology annual meeting. Miami, FL. March 2013.

190. Off-label uses of ustekinumab (invited speaker). American Academy of Dermatology annual meeting. Miami, FL. March 2013.
191. Exploring psoriatic cellular immunity (invited speaker). American Academy of Dermatology annual meeting. Miami, FL. March 2013.
192. Herpesviruses (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2013.
193. Psoriatic arthritis (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2013.
194. Basic science psoriasis update (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2013.
195. Structure and function of skin (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2013.
196. Psoriasis variants (invited speaker). Maui Derm NP+PA 2013: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2013.
197. Emerging concepts in psoriasis: immunopathology and burden of disease (invited speaker). Novartis National Speaker Training Meeting. Chicago, IL. July 2013.
198. Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis subjects with psoriatic arthritis: a subanalysis of a phase 3, multicenter, double-blind, placebo-controlled study (poster). European Academy of Dermatology and Venereology annual meeting. Istanbul, Turkey. October 2013.
199. Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis subjects with psoriatic arthritis: a subanalysis of a phase 3, multicenter, double-blind, placebo-controlled study (poster). American College of Rheumatology annual meeting. San Diego, CA. October 2013.
200. HIV update for 2014 (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Wailea, HI. January 2014.
201. Cutaneous immunology (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Wailea, HI. January 2014.
202. Immunology of psoriasis (invited speaker). Maui Derm 2014: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2014.
203. Ixekizumab rapidly improves psoriasis within 2 weeks (poster). Maui Derm 2014: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2014.
204. Off-label use of ustekinumab (invited speaker). American Academy of Dermatology annual meeting. Denver, CO. March 2014.
205. Off-label use of biologics (invited speaker). American Academy of Dermatology annual meeting. Denver, CO. March 2014.
206. Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study (invited speaker). American Academy of Dermatology annual meeting. Denver, CO. March 2014.
207. Immunology of psoriasis (invited speaker). American Academy of Dermatology annual meeting. Denver, CO. March 2014.
208. Secukinumab efficacy and safety: results from the first study of secukinumab in prefilled syringes in subjects with chronic plaque-type psoriasis response at 12 weeks (FEATURE) (poster). American Academy of Dermatology annual meeting. Denver, CO. March 2014.

209. Secukinumab efficacy and safety: results from the first study of secukinumab in prefilled syringes in subjects with chronic plaque-type psoriasis response at 12 weeks (FEATURE) (poster). Dermatology Nurses' Association annual meeting. Orlando, FL. May 2014.
210. Impact of ixekizumab on blood neutrophil levels and the incidence of infections caused by *Candida albicans* or *Staphylococcus aureus* (invited speaker). Society for Investigative Dermatology annual meeting. Albuquerque, NM. May 2014.
211. Psoriasis: general features and approach to the patient (invited speaker). Psoriasis Summit, Eli Lilly and Company. Barcelona, Spain. May 2014.
212. Secukinumab reduces hsCRP levels in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a sub-analysis from the phase 3 ERASURE study (poster). European League Against Rheumatism annual meeting. Paris, France. June 2014.
213. Candidiasis in secukinumab-treated subjects is non-serious and transient: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis (poster). Federation of Clinical Immunology Societies annual meeting. Chicago, IL. June 2014.
214. Structure and function of skin (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
215. Immunology 101: the basics (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
216. Immunology 101: psoriasis, atopic dermatitis, and melanoma immunology (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
217. Immunology 101: HIV and the skin (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
218. Psoriasis case presentations (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
219. The psoriasis pipeline (invited speaker). Maui Derm NP+PA 2014: Advances & Approaches for the Dermatologic Practitioner. Park City, UT. June 2014.
220. Ustekinumab therapy for psoriasis (invited speaker). Pacific Dermatologic Association annual meeting. Vancouver, Canada. August 2014.
221. JAK inhibitors as treatment in psoriasis: understanding efficacy (invited speaker). 44th Annual European Society for Dermatological Research Meeting. Copenhagen, Denmark. September 2014.
222. Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis (poster). 44th Annual European Society for Dermatological Research Meeting. Copenhagen, Denmark. September 2014.
223. Crossfire symposium: the advent of biosimilars (invited speaker). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
224. Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: pooled analysis of 10 phase 2/3 studies (poster). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
225. Secukinumab shows efficacy regardless of baseline disease severity in subjects with moderate-to-severe plaque psoriasis: a pooled analysis from four phase 3 studies

- (poster). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
226. Secukinumab decreases inflammation as measured by a biomarker hsCRP in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: subanalyses from two phase 3 studies (poster). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
227. Effect of ixekizumab treatment on plaque characteristics and psoriasis in different body regions: results from a phase 2 randomized placebo controlled trial (poster). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
228. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy: a phase 2b study (poster). European Academy of Dermatology and Venereology annual meeting. Amsterdam, Netherlands. October 2014.
229. Candidiasis in secukinumab-treated subjects: a pooled analysis of data from 10 clinical trials in moderate-to-severe plaque psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2014.
230. Secukinumab is efficacious in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2014.
231. Relevance of ixekizumab for complete resolution and patient impact (invited speaker). Psoriasis Summit, Eli Lilly and Company. Indianapolis, IN. October 2014.
232. Update on current and future biologics for psoriasis (invited speaker). Skin Disease Education Foundation 15th Annual Las Vegas Dermatology Seminar. Las Vegas, NV. October 2014.
233. Non-serious and transient candidiasis in secukinumab-treated subjects: a pooled analysis of data from 10 clinical trials in moderate-to-severe plaque psoriasis (poster). Skin Disease Education Foundation 15th Annual Las Vegas Dermatology Seminar. Las Vegas, NV. October 2014.
234. Secukinumab efficacy and safety using pre-filled syringes in subjects with moderate-to-severe plaque psoriasis: results from the FEATURE phase 3 study (poster). Society of Dermatology Physician Assistants Fall Dermatology Conference. San Diego, CA. November 2014.
235. Biosimilars update (invited speaker). International Psoriasis Council Think Tank. London, England. December 2014.
236. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis (poster). Psoriasis from Gene to Clinic 7th International Congress. London, United Kingdom. December 2014.
237. AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis (poster). Psoriasis from Gene to Clinic 7th International Congress. London, United Kingdom. December 2014.
238. Secukinumab administration by pre-filled syringe maintains reduction in severity of plaque psoriasis over 52 weeks: results of the FEATURE trial (poster). Psoriasis from Gene to Clinic 7th International Congress. London, United Kingdom. December 2014.

239. Highly sensitive and drug tolerant immunogenicity screening assay for ixekizumab, an anti-IL-17A antibody, using an affinity capture elution approach (poster). Psoriasis from Gene to Clinic 7th International Congress. London, United Kingdom. December 2014.
240. Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to- severe plaque psoriasis (poster). Maui Derm 2015: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2015.
241. Secukinumab decreases inflammation as measured by biomarker hsCRP in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: subanalyses from two phase 3 studies (poster). Maui Derm 2015: Advances in Cosmetic & Medical Dermatology. Wailea, HI. January 2015.
242. Dupilumab improves patient-reported outcomes (PROs) in a phase 2 study in adults with moderate-to-severe atopic dermatitis (poster). American Academy of Allergy, Asthma & Immunology annual meeting. Houston, TX. February 2015.
243. Understanding the cellular and molecular dimension of psoriasis: implications for management with biologic therapies (invited speaker). 39th Annual Hawaii Dermatology Seminar. Koloa, HI. March 2015.
244. Secukinumab treatment maintains efficacy in moderate to severe plaque psoriasis through second year of treatment: a randomized extension of the ERASURE and FIXTURE studies (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
245. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12- and 60-week results from UNCOVER-1 (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
246. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 16-week results from the CLEAR study (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
247. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) inadequately controlled by topical therapies: final results of a phase 2b study (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
248. Communicating the burden of psoriasis to patients (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
249. Biologics as immunomodulators (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
250. Patient-centered approach to psoriasis care (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
251. Innovators and biosimilars: the scientific basis for their approval (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
252. Similar drug but different patients: possibilities for extrapolation to dermatology (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
253. Off-label biologics for psoriasis variants, pityriasis rubra pilaris, and atopic dermatitis (invited speaker). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.

254. Secukinumab long-term self-administration by prefilled syringe or autoinjector/pen is highly acceptable to subjects with moderate to severe plaque psoriasis (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
255. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human *in vitro* assays (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
256. Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
257. Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: a pooled phase 3 safety analysis (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
258. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12 (poster). American Academy of Dermatology annual meeting. San Francisco, CA. March 2015.
259. Biosimilar update: relevance for dermatology clinical practice (invited speaker). PSOfuture: New Directions from the Eternal City. Rome, Italy. April 2015.
260. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 16-week results from the CLEAR study (poster). SDPA Annual Summer Dermatology Conference 2015. Las Vegas, NV. June 2015.
261. Secukinumab long-term self-administration by prefilled syringe or autoinjector/pen is highly acceptable to subjects with moderate to severe plaque psoriasis (poster). SDPA Annual Summer Dermatology Conference 2015. Las Vegas, NV. June 2015.
262. Secukinumab is superior to ustekinumab in clearing the skin and improving the QOL of subjects with moderate to severe plaque psoriasis: 16-week results from the CLEAR study (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
263. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in phase 3 clinical trials: treatment-emergent anti-drug antibodies and subject level clinical correlation (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
264. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 randomized clinical trials (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
265. AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
266. Maintenance of efficacy among patients who achieve sPGA (0,1): 60-week results from UNCOVER-1, a phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
267. Complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: an analysis from UNCOVER-2, a phase 3 clinical trial of ixekizumab (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.

268. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1) (poster). 23rd World Congress of Dermatology. Vancouver, Canada. June 2015.
269. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human *in vitro* assays (poster). Maui Derm NP+PA 2015: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2015.
270. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12 (poster). 4th World Psoriasis & Psoriatic Arthritis Conference. Stockholm, Sweden. July 2015.
271. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis (poster). 4th World Psoriasis & Psoriatic Arthritis Conference. Stockholm, Sweden. July 2015.
272. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study (poster). 45th Annual European Society for Dermatological Research Meeting. Rotterdam, Netherlands. September 2015.
273. Sensitivity and drug tolerance of anti-drug antibody screening assays for ixekizumab (poster). 45th Annual European Society for Dermatological Research Meeting. Rotterdam, Netherlands. September 2015.
274. Analysis of neutropenia with ixekizumab in 7 clinical studies of psoriasis (poster). 45th Annual European Society for Dermatological Research Meeting. Rotterdam, Netherlands. September 2015.
275. Complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: an analysis from UNCOVER-1, a phase 3 clinical trial of ixekizumab (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
276. Safety and tolerability of ixekizumab: analysis of neutropenia in 7 clinical studies of moderate-to-severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
277. Differences in Dermatology Life Quality Index (DLQI) and Psoriasis Symptom Inventory (PSI) scores among patients with complete (PASI 100) and almost complete (PASI 90 to <100, PASI 75 to <90) skin clearance (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
278. More symptom free days, less residual disease and lower quality of life impairment in patients with moderate to severe plaque psoriasis who achieve sPGA 0 vs 1 (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
279. Improvement in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
280. Changes in C-reactive protein levels following brodalumab treatment in three phase 3, randomized, placebo-controlled studies for moderate to severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.

281. Secukinumab administration by pre-filled syringe maintains efficacy in moderate to severe plaque psoriasis over two years (100 weeks): results of the FEATURE trial (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
282. Secukinumab exhibits low immunogenicity during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
283. Secukinumab withdrawal leads to loss of treatment responses in a majority of subjects with plaque psoriasis with re-treatment resulting in rapid regain of responses: a pooled analysis of two phase 3 trials (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
284. Secukinumab delivers greater improvement in health-related quality of life compared to ustekinumab in subjects with moderate to severe plaque psoriasis: 16-week data from the CLEAR study (poster). European Academy of Dermatology and Venereology annual meeting. Copenhagen, Denmark. October 2015.
285. What can we expect by blocking different targets in immunopathogenetic pathways in psoriasis? Slovenian National Dermatovenereology Congress. Maribor, Slovenia. November 2015.
286. Secukinumab improves skin symptoms and physical functioning compared with ustekinumab in patients with moderate to severe psoriasis with concomitant psoriatic arthritis: sub analysis of a randomized, double blind, parallel-group, active comparator-controlled phase 3b trial (poster). American College of Rheumatology annual meeting. San Francisco, CA. November 2015.
287. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 randomized clinical trials (poster). Society for Dermatology Physician Assistants annual meeting. Orlando, FL. November 2015.
288. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 randomized clinical trials (poster). Winter Clinical Dermatology Conference. Koloa, HI. January 2016.
289. Important psoriasis papers published in 2015 (invited speaker). Maui Derm 2016. Wailea, HI. January 2016.
290. Biosimilars: pre-clinical development (invited speaker). Maui Derm 2016. Wailea, HI. January 2016.
291. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 randomized clinical trials (poster). Maui Derm 2016. Wailea, HI. January 2016.
292. From pathogenesis to new biologic therapies: an emerging approach to treatment of psoriasis and its comorbidities to improve patient outcomes and quality of life (invited speaker). 40th Annual Hawaii Dermatology Seminar. Waikoloa, HI. February 2016.
293. Maintenance of efficacy results from UNCOVER-1: a phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis (poster). 40th Annual Hawaii Dermatology Seminar. Waikoloa, HI. February 2016.
294. Secukinumab administration by pre-filled syringe maintains efficacy in moderate-to-severe plaque psoriasis over 100 weeks: results of the FEATURE trial (poster). 40th Annual Hawaii Dermatology Seminar. Waikoloa, HI. February 2016.

295. Secukinumab delivers greater improvement in health-related quality of life compared to ustekinumab in subjects with moderate-to-severe plaque psoriasis: 16-week data from the CLEAR study (poster). 40th Annual Hawaii Dermatology Seminar. Waikoloa, HI. February 2016.
296. Secukinumab re-treatment shows rapid regain or treatment responses: a pooled analysis of two phase 3 trials in psoriasis (poster). 40th Annual Hawaii Dermatology Seminar. Waikoloa, HI. February 2016.
297. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a pooled analysis of two phase 2 clinical trials (poster). South Beach Symposium. Miami Beach, FL. February 2016.
298. Secukinumab demonstrates sustained superior efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study (invited speaker). Annual Novartis MSL Meeting. Washington, DC. March 2016.
299. Cosentyx for psoriasis: where does it currently stand in the marketplace (invited speaker). Annual Novartis MSL Meeting. Washington, DC. March 2016.
300. Biosimilars: pre-clinical development (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
301. Targeting the IL-23/Th17 pathway in psoriasis (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
302. Biologics for atopic dermatitis: a new era begins (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
303. Efficacy and safety of continuous ixekizumab treatment for 60 weeks in moderate-to-severe plaque psoriasis: results from the UNCOVER-3 trial (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
304. Biosimilars update (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
305. Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
306. Safety profile of patients achieving complete or near complete resolution of moderate-to-severe psoriasis after 12 weeks of etanercept or ixekizumab: integrated analyses from UNCOVER-2 and UNCOVER-3 (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
307. Secukinumab exhibits a favorable safety profile during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
308. Secukinumab maintains reductions in PASI through second year of treatment: a randomized extension of the ERASURE and FIXTURE studies in plaque psoriasis (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
309. Secukinumab administration by prefilled syringe maintains efficacy in moderate to severe plaque psoriasis over 100 weeks: results of the FEATURE trial (invited speaker). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
310. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 randomized clinical trials (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.

311. Complete or near complete resolution of psoriasis is associated with greater improvements in health related quality of life, itching, and skin pain: an integrated analysis of UNCOVER-2 and UNCOVER-3 (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
312. Ixekizumab shows efficacy and safety in patients who failed bi-weekly etanercept therapy: analysis from UNCOVER-2, a phase 3 randomized clinical trial in psoriasis (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
313. Efficacy and safety of ixekizumab in psoriasis patients who failed to reach PASI 75 on etanercept: subanalysis of UNCOVER-3 (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
314. Efficacy and safety of ixekizumab over four years of open-label treatment in a phase 2 study in chronic plaque psoriasis (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
315. Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
316. Secukinumab demonstrates sustained superior efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
317. Secukinumab-treated subjects experience low rates of *Candida* and recurrent *Candida* infections: a pooled analysis from 10 phase 2 and 3 clinical studies in psoriasis (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
318. Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: Analysis of scalp, palmoplantar, and nail psoriasis subgroups (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
319. Selective blockade of IL-23p19 with BI 655066 is associated with significant improvement in QoL outcomes compared with ustekinumab in patients with moderate-to-severe plaque psoriasis
320. Selective blockade of IL-23p19 with BI 655066 is associated with clinical responses superior to ustekinumab in patients with moderate-to-severe plaque psoriasis: Results from a 48-week Phase II study (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
321. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of 3 randomized controlled trials (poster). American Academy of Dermatology annual meeting. Washington, DC. March 2016.
322. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Noah Worcester Dermatological Society 58th Annual Meeting. Marana, AZ. April 2016.
323. Targeting IL-17A in psoriasis confers high degrees of both efficacy and safety. Noah Worcester Dermatological Society 58th Annual Meeting. Marana, AZ. April 2016.
324. Science & immunology of psoriasis and associated co-morbidities. A+MD Annual Meeting. Coeur d'Alene, ID. May 2016.
325. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. A+MD Annual Meeting. Coeur d'Alene, ID. May 2016.
326. Management of moderate-to-severe psoriasis. A+MD Annual Meeting. Coeur d'Alene, ID. May 2016.

327. Atopic dermatitis – topicals and biologics – what’s new. A+MD Annual Meeting. Coeur d’Alene, ID. May 2016.
328. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Taltz National Faculty Training Meeting. Dallas, TX. June 2016.
329. Cutaneous immunology: boot camp basics (invited speaker). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
330. Treating psoriasis for high levels of clearance (invited speaker). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
331. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab (poster). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
332. Secukinumab demonstrates sustained superior efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study (poster). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
333. Secukinumab exhibits a favorable safety profile during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis (poster). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
334. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis (poster). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
335. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials (poster). Maui Derm NP+PA 2016: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2016.
336. Sustained improvements in skin symptoms, physical functioning and quality of life with secukinumab versus ustekinumab in patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis: 52 week results from the CLEAR study (poster). Annual European Congress of Rheumatology. London, England. June 2016.
337. Efficacy and safety of ixekizumab over four years of open-label treatment in a phase 2 study in chronic plaque psoriasis (poster). Psoriasis 2016. Paris, France. July 2016.
338. Efficacy and safety of ixekizumab in psoriasis patients who failed to reach PASI 75 on etanercept: subanalysis of UNCOVER-3 (poster). Psoriasis 2016. Paris, France. July 2016.
339. Time course of ixekizumab drug levels and the relationship at week 60 to efficacy in patients with moderate-to-severe plaque psoriasis (UNCOVER-3) (poster). Psoriasis 2016. Paris, France. July 2016.
340. Secukinumab exhibits low immunogenicity during 3 years of treatment in subjects with

- moderate to severe plaque psoriasis (poster). Psoriasis 2016. Paris, France. July 2016.
341. Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling (poster). American Academy of Dermatology annual summer meeting. Boston, MA. July 2016.
 342. Secukinumab skin clearance is associated with greater improvements in skin-related quality of life (poster). American Academy of Dermatology annual summer meeting. Boston, MA. July 2016.
 343. Ixekizumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis (poster). European Society for Dermatological Research annual meeting. Munich, Germany. September 2016.
 344. Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3 (poster). European Society for Dermatological Research annual meeting. Munich, Germany. September 2016.
 345. IL-23 biology and its role in psoriasis pathogenesis (invited speaker). Janssen Psoriasis Advisory Council. Philadelphia, PA. September 2016.
 346. Ixekizumab treatment enables rapid improvements in Health-related quality of life and itch: results from UNCOVER-2 and UNCOVER-3 (invited speaker). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. September 2016.
 347. IL-23 biology and its role in psoriasis pathogenesis (invited speaker). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. September 2016.
 348. Efficacy and safety of ixekizumab in patients previously treated with etanercept (poster). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. September 2016.
 349. Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab (poster). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. September 2016.
 350. A “patient-tailored” maintenance dosing study for ustekinumab in moderate-to-severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. September 2016.
 351. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of moderate to severe psoriasis in the phase 3 VOYAGE 1 trial (invited speaker). European Academy of Dermatology and Venereology annual meeting. Vienna, Austria. October 2016.
 352. The THRIVE initiative: targeting psoriasis pathology with new biologics to improve patients’ outcomes and quality of life (invited speaker). Los Angeles, CA. October 2016.
 353. Targeting psoriasis pathology with new biologics to improve patients’ outcomes and quality of life (invited speaker). SDEF Women’s and Pediatric Dermatology Meeting. Newport Beach, CA. October 2016.
 354. EADV 2016: review of efficacy of new biologics (invited speaker). Chicago, IL. October 2016.
 355. Secukinumab maintains reductions in PASI through second year of treatment: a

- randomized extension of the ERASURE and FIXTURE studies in plaque psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2016.
356. Secukinumab retreatment shows rapid Regain of treatment responses: a pooled analysis of two phase 3 trials in psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2016.
357. Secukinumab exhibits a favorable safety profile during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2016.
358. Secukinumab-treated subjects experience low rates of *Candida* and recurrent *Candida* infections: a pooled analysis from 10 phase 2 and 3 clinical studies in psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2016.
359. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of moderate-to-severe psoriasis in the phase 3 VOYAGE 1 trial (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2016.
360. Selective IL-23 blockers (invited speaker). Sun Pharma Advisory Board. Philadelphia, PA. October 2016.
361. Conducting industry-sponsored studies and clinical trials (invited speaker). Pediatric Dermatology Research Alliance annual conference. Irving, TX. November 2016.
362. Secukinumab retreatment shows rapid regain of treatment responses: a pooled analysis of two phase 3 trials in psoriasis (poster). Society of Dermatology Physician Assistants Meeting Fall 2016. Las Vegas, NV. November 2016.
363. Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2) (poster). Society of Dermatology Physician Assistants Meeting Fall 2016. Las Vegas, NV. November 2016.
364. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of moderate-to-severe psoriasis in the phase 3 VOYAGE 1 trial (poster). 17th Annual Las Vegas Dermatology Seminar & the 13th Annual SDEF Psoriasis Forum. Las Vegas, NV. November 2016.
365. IL-17A biology and its role in psoriasis pathogenesis (invited speaker). *Terapeutica Biologica/Immunologica en Dermatologia*. Barcelona, Spain. November 2016.
366. Challenges for doctors and patients in the treatment of psoriasis (invited speaker). UCB Conference. Brussels, Belgium. December 2016.
367. Secukinumab 300 mg is more efficacious than ustekinumab 90 mg at week 16: analysis of the CLEAR study (poster). Winter Clinical Dermatology Conference. Kohala Coast, HI. January 2017.
368. Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2) (poster). Winter Clinical Dermatology Conference. Kohala Coast, HI. January 2017.
369. Comparative efficacy of two dosages of brodalumab in psoriasis patients in different weight subgroups (poster). 41st Annual Hawaii Dermatology Seminar. Wailea, HI. January 2017.
370. Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2) (poster). 41st Annual Hawaii Dermatology Seminar. Wailea, HI. January 2017.

371. Targeting psoriasis pathology with new biologics to improve patients' outcomes and quality of life (invited speaker). 41st Annual Hawaii Dermatology Seminar. Wailea, HI. January 2017.
372. Insights into the Taltz label. Taltz National Speaker's Training. Phoenix, AZ. February 2017.
373. PSTELLAR: review of study results. PSTELLAR Investigators Meeting. Portland, OR. February 2017.
374. Clinical insights on Taltz (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
375. Treatment of atopic dermatitis in 2017 (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
376. Emerging atopic dermatitis pipeline (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
377. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids: a 1-year, randomized, placebo-controlled phase 3 trial (CHRONOS) (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
378. Emerging biologics for atopic dermatitis (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
379. Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: results from the phase 3 VOYAGE 1 study (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
380. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3) (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
381. Clearing of psoriasis within different body regions following 12 weeks of treatment with ixekizumab (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
382. Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3) (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
383. Patient-reported symptoms and signs in patients with moderate-to-severe plaque psoriasis treated with guselkumab or adalimumab: results from VOYAGE 1, a phase III clinical trial (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
384. IL-23 biology and its role in psoriasis pathogenesis (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
385. Biosimilars: pre-clinical development (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
386. A randomized, double-blind, multicenter study to compare the efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (GP2017) with originator adalimumab in patients with moderate-to-severe chronic plaque psoriasis (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.

387. Biosimilars update (invited speaker). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
388. Secukinumab retreatment shows rapid recapture of treatment response: an analysis of a phase 3 extension trial in psoriasis (poster). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
389. Correlation between PASI response and improvement in health-related quality of life over time: results from a phase III clinical trial VOYAGE 1 (poster). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
390. Consistency of response across subgroups of patients with psoriasis treated with guselkumab: results from the VOYAGE 1 and 2 trials (poster). American Academy of Dermatology annual meeting. Orlando, FL. March 2017.
391. Certolizumab pegol treatment for chronic plaque psoriasis: 16-week primary results from two phase 3, multicenter, randomized, placebo-controlled studies. American Academy of Dermatology annual meeting (poster). Orlando, FL. March 2017.
392. Emerging biologics for atopic dermatitis (invited speaker). Maui Derm 2017. Wailea, HI. March 2017.
393. Management of moderate-to-severe atopic dermatitis (AD) with dupilumab and concomitant topical corticosteroids (TCS): a 1-year, randomized, placebo-controlled phase 3 trial (CHRONOS) (poster). Maui Derm 2017. Wailea, HI. March 2017.
394. Secukinumab 300 mg is more efficacious than ustekinumab 90 mg: analysis of the CLEAR study (poster). Maui Derm 2017. Wailea, HI. March 2017.
395. Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: results from the phase 3 VOYAGE 1 study (poster). Maui Derm 2017. Wailea, HI. March 2017.
396. Patient-reported symptoms and signs in patients with moderate-to-severe plaque psoriasis treated with guselkumab or adalimumab: results from VOYAGE 1, a phase III clinical trial (poster). Maui Derm 2017. Wailea, HI. March 2017.
397. Correlation between PASI response and improvement in health-related quality of life over time: results from a phase III clinical trial VOYAGE 1 (poster). Maui Derm 2017. Wailea, HI. March 2017.
398. Consistency of response across subgroups of patients with psoriasis treated with guselkumab: results from the VOYAGE 1 and 2 trials (poster). Maui Derm 2017. Wailea, HI. March 2017.
399. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis (invited speaker). Society of Dermatology Physician Assistants Annual Meeting. San Diego, CA. June 2017.
400. Update on biologics for psoriasis (invited speaker). Dermira University Lecture. Palo Alto, CA. June 2017.
401. Existing biologic therapies and how they fit together (invited speaker). Purdue Pharma Scientific Symposium. Stamford, CT. June 2017.
402. Cardiovascular disease and psoriasis: what you need to know and what you should tell your patients. Alabama Dermatology Society annual meeting. Destin, FL. June 2017.
403. Clear skin with no side effects as a modern treatment goal for all your patients with psoriasis. Alabama Dermatology Society annual meeting. Destin, FL. June 2017.
404. Tremfya: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Nationally broadcast webinar. August 2017.

405. A phase 2, randomized, double-blinded, placebo-controlled study of bimekizumab in moderate-to-severe plaque psoriasis (invited speaker). Bimekizumab Advisory Board. Geneva, Switzerland. September 2017.
406. Efficacy, health-related outcomes, and safety of ixekizumab for up to five years of open-label treatment in a phase 2 study in chronic plaque psoriasis (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
407. Efficacy and safety of dupilumab with concomitant topical corticosteroids in moderate-to-severe atopic dermatitis over 1-year as assessed by baseline demographics (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
408. Understanding cytokine pathways in psoriasis (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
409. The importance of the IL-23/Th17 pathway in the pathogenesis and treatment of psoriasis (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
410. Targeting IL-23 in psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
411. Two-year efficacy and safety of guselkumab for treatment of moderate to severe psoriasis: phase 3 VOYAGE 1 trial (invited speaker). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
412. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
413. Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
414. Clinical efficacy of tildrakizumab, an anti-IL-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: results from long-term extensions to two phase III clinical studies (reSURFACE 1 and reSURFACE 2) (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
415. Impact of body weight on efficacy of tildrakizumab at week 12 in moderate-to-severe chronic plaque psoriasis (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
416. Association between psoriasis area and severity index and physician's global assessment responses in moderate-to-severe chronic plaque psoriasis studies of tildrakizumab (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
417. Efficacy of tildrakizumab for moderate-to-severe chronic plaque psoriasis: pooled analysis of three randomized controlled studies at weeks 12 and 28 (poster). European

- Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
418. A phase III confirmatory study comparing GP2017 with reference adalimumab in patients with moderate-to-severe chronic plaque psoriasis: 51 week results from the ADACCESS study (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 419. Continuous treatment with secukinumab 300 mg demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in moderate to severe plaque psoriasis: two year results from the CLEAR study (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 420. Efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: a pooled analysis from VOYAGE 1 and VOYAGE 2 (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 421. Efficacy of guselkumab in previously treated patients with moderate to severe plaque psoriasis: an analysis from VOYAGE 1 and VOYAGE 2 (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 422. Certolizumab pegol for the treatment of chronic plaque psoriasis: DLQI and WPAI patient-reported outcomes from an ongoing phase 3, multicenter, randomized, active- and placebo-controlled study (CIMPACT) (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 423. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: results of a 32-week re-randomized maintenance period from an ongoing phase 3, multicenter, randomized, active- and placebo-controlled study (CIMPACT) (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 424. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: 48-week results from two ongoing phase 3, multicenter, randomized, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) (poster). European Academy of Dermatology and Venereology annual meeting. Geneva, Switzerland. September 2017.
 425. Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: results through 108 weeks in a randomised, phase III clinical trial (UNCOVER-3) (poster). European Society for Dermatological Research annual meeting. Salzburg, Austria. September 2017.
 426. Clinical trials in psoriatic disease (invited speaker). National Psoriasis Foundation webinar. October 2017.
 427. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23 (invited speaker). Costal Dermatology Society annual meeting. Portland, OR. October 2017.
 428. The biologic era for atopic dermatitis (invited speaker). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
 429. Clinical insights on Taltz (invited speaker). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.

430. Efficacy and safety of dupilumab with concomitant topical corticosteroids in moderate-to-severe atopic dermatitis over 1-year, as assessed by baseline demographics (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
431. A randomized, double-blind, multicenter study to compare the efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (GP2017) with originator adalimumab in patients with moderate-to-severe chronic plaque psoriasis (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
432. Secukinumab provides complete or almost-complete psoriasis clearance in moderate-to-severe plaque psoriasis: pooled analysis of 4 phase 3 trials (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
433. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: results of a 32-week re-randomized maintenance period from an ongoing phase 3, multicenter, randomized, active- and placebo-controlled study (CIMPACT) (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
434. Certolizumab pegol for the treatment of chronic plaque psoriasis: DLQI and WPAI patient-reported outcomes from an ongoing phase 3, multicenter, randomized, active- and placebo-controlled study (CIMPACT) (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
435. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: 48-week results from two ongoing phase 3, multicenter, randomized, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
436. Clinical responses in patients with moderate-to-severe plaque psoriasis following withdrawal and re-treatment with risankizumab or switching from ustekinumab to risankizumab (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
437. Neuropsychiatric adverse events in brodalumab psoriasis studies (poster). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2017.
438. Participating in a psoriasis clinical trial: the pros and cons (invited speaker). National Psoriasis Foundation webinar. October 2017.
439. Advances in targeted therapy for psoriasis and atopic dermatitis: bench-to-bedside success stories (invited speaker). University of Cincinnati Smith H. & Lucille Gibson, M.D., Endowed Lecture in Dermatology. Cincinnati, OH. October 2017.
440. Clinical insights: why is Tremfya exciting? Janssen European Launch Meeting for Tremfya (invited speaker). London, England. November 2017.
441. Immunogenicity with tildrakizumab, an anti-IL-23p19 monoclonal antibody, in a pooled analysis of three randomized controlled trials in patients with chronic plaque psoriasis (poster). Psoriasis from Gene to Clinic meeting. London, England. November 2017.
442. Secukinumab pooled and long term safety: analysis of 19 psoriasis clinical trials up to 5 years of treatment (poster). Psoriasis from Gene to Clinic meeting. London, England. November 2017.
443. Absolute psoriasis area and severity index improvement through 2 years of guselkumab treatment in the VOYAGE 1 trial of patients with plaque psoriasis (poster). Psoriasis from Gene to Clinic meeting. London, England. November 2017.
444. Targeting IL-17: findings from recent clinical trials (invited speaker). Lilly Sponsored Lecture. Psoriasis from Gene to Clinic meeting. London, England. November 2017.

445. Efficacy and safety of risankizumab, an IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase 3 IMMhance trial (invited speaker). Psoriasis from Gene to Clinic meeting. London, England. December 2017.
446. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of 3 randomized controlled trials (invited speaker). Psoriasis from Gene to Clinic meeting. London, England. December 2017.
447. Clinical secukinumab data: pooled long-term safety (from 19 studies), exposure-response relationship, FUTURE 5 (invited speaker). Novartis Advisory Board. London, England. December 2017.
448. IL-23 as a target for psoriasis: a bench-to-bedside success story (invited speaker). Yamanashi University. Kofu City, Japan. December 2017.
449. Clinical insights from the U.S.: why is Tremfya exciting? Janssen Japanese Launch Meeting for Tremfya (invited speaker). Kochi, Japan. December 2017.
450. What is the best target for psoriasis: IL-23 versus IL-17A? (invited speaker). 42nd Annual Meeting of the Japanese Society for Investigative Dermatology. Kochi, Japan. December 2017.
451. Guselkumab Roundtable Discussion (invited speaker). Janssen Japanese Launch Meeting for Tremfya (invited speaker). Kochi, Japan. December 2017.
452. Role of IL-23 in psoriasis pathogenesis (invited speaker). 42nd Annual Meeting of the Japanese Society for Investigative Dermatology. Kochi, Japan. December 2017.
453. Safety of certolizumab pegol in chronic plaque psoriasis: cumulative data over 48 weeks' exposure from phase 3, multicenter, randomized, placebo-controlled studies (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
454. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of 3 randomized controlled trials (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
455. Efficacy of guselkumab in previously treated patients with moderate-to-severe plaque psoriasis: an analysis from VOYAGE 1 and VOYAGE 2 (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
456. Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: Phase 3 VOYAGE 1 trial (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
457. Secukinumab's pooled and long-term safety: analysis of 19 psoriasis clinical trials up to 5 years of treatment (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
458. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
459. Secukinumab provides complete or almost-complete psoriasis clearance in moderate-to-severe plaque psoriasis: pooled analysis of 4 phase 3 trials (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
460. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.

461. Clinical efficacy of tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies (poster). Winter Clinical Dermatology Conference. Kaanapali, HI. January 2018.
462. Update on psoriasis pathogenesis (invited speaker). Maui Derm 2018. Wailea, HI. January 2018.
463. The biologic era for atopic dermatitis (invited speaker). Maui Derm 2018. Wailea, HI. January 2018.
464. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23 (invited speaker). Maui Derm 2018. Wailea, HI. January 2018.
465. Incidence of inflammatory bowel disease in patients treated with secukinumab: pooled analysis of 21 phase 3/4 clinical trials of psoriasis, psoriatic Arthritis, and ankylosing spondylitis (poster). Maui Derm 2018. Wailea, HI. January 2018.
466. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial (poster). Maui Derm 2018. Wailea, HI. January 2018.
467. Efficacy of guselkumab in previously treated patients with moderate-to-severe plaque psoriasis: an analysis from VOYAGE 1 and VOYAGE 2 (poster). Maui Derm 2018. Wailea, HI. January 2018.
468. Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 VOYAGE 1 trial (poster). Maui Derm 2018. Wailea, HI. January 2018.
469. Clinical efficacy of tildrakizumab, an anti-IL-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2) (poster). Maui Derm 2018. Wailea, HI. January 2018.
470. Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: a pooled analysis from two ongoing, phase 3 studies (CIMPASI-1 and CIMPASI-2) (poster). Maui Derm 2018. Wailea, HI. January 2018.
471. Biologics for atopic dermatitis (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
472. Should TNF blockers be used first line in patients with psoriasis and psoriatic arthritis? (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
473. Treatment of atopic dermatitis in 2018 (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
474. Taltz: perspectives from dual specialties (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
475. Biologics for atopic dermatitis (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
476. Secukinumab: highly effective and durable treatment for psoriasis and psoriatic arthritis patients (invited speaker). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
477. Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.

478. Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
479. Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: pooled analysis of three randomized controlled studies (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
480. Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
481. Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: a pooled subanalysis of ongoing, phase 3 studies (CIMPASI-1, CIMPASI-2, CIMPACT) (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
482. Ixekizumab provides greater cumulative benefits versus ustekinumab over 24 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blind phase 3b clinical trial (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
483. Secukinumab's pooled and long-term safety remains favorable up to 5 years of treatment in 19 psoriasis clinical trials (poster). American Academy of Dermatology annual meeting. San Diego, CA. February 2018.
484. A-101 (hydrogen peroxide) topical solution safety and efficacy in patients with seborrheic keratoses: results from two identical randomized, double-blind, placebo-controlled, phase 3 studies (poster). International Investigative Dermatology meeting. Orlando, FL. May 2018.
485. Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (LIBERTY, SOLO 1&2, CHRONOS, CAFE) (poster). International Investigative Dermatology meeting. Orlando, FL. May 2018.
486. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis (invited speaker). East Atopic Dermatitis Symposium. Tokyo, Japan. May 2018.
487. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis (invited speaker). West Atopic Dermatitis Symposium. Osaka, Japan. May 2018.
488. Dupilumab (Dupixent®): a bench-to-bedside success story for atopic dermatitis (invited speaker). AD Expert Meeting. Seoul, South Korea. May 2018.
489. Targeting IL-17 versus IL-23 in psoriasis (invited speaker). Dermatology Expert Lecture Series. Novartis. East Hanover, NJ. June 2018.
490. Incidence of inflammatory bowel disease in patients treated with secukinumab: pooled analysis of 21 phase 3/4 clinical trials of psoriasis, psoriatic arthritis, and ankylosing spondylitis (poster). Maui Derm NP+PA 2015: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2018.
491. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial (poster). Maui Derm NP+PA 2015: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2018.
492. Safety of dupilumab in moderate-to-severe atopic dermatitis: clinical laboratory results from three phase 3 clinical trials (LIBERTY AD SOLO 1, SOLO 2, and CHRONOS (poster). Maui Derm NP+PA 2015: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2018.

493. Neuropsychiatric adverse events in brodalumab psoriasis studies (poster). Maui Derm NP+PA 2015: Advances & Approaches for the Dermatologic Practitioner. Colorado Springs, CO. June 2018.
494. A closer look at Taltz®. SDPA Annual Summer Dermatology Conference 2018. Seattle, WA. June 2018.
495. Secukinumab is superior to ustekinumab in clearing skin of patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial (poster). SDPA Annual Summer Dermatology Conference 2018. Seattle, WA. June 2018.
496. Secukinumab's long-term safety remains favourable up to 5 years of treatment (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
497. Predictors of response to tildrakizumab for moderate to severe chronic plaque psoriasis (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
498. Durable reduction in absolute PASI with certolizumab pegol in patients with chronic plaque psoriasis (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
499. Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
500. Safety of certolizumab pegol over 48 weeks in chronic plaque psoriasis phase 3 trials (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
501. Durability of response in certolizumab pegol-treated patients over 48 weeks in CIMPASI-1 & 2 trials (poster). 5th World Psoriasis and Psoriatic Arthritis Conference. Stockholm, Sweden. July 2018.
502. Dupilumab improves atopic dermatitis equally well in all anatomical regions: data from the LIBERTY phase 3 clinical trials (poster). British Association of Dermatology Annual Meeting. Edinburgh, Scotland. July 2018.
503. Dupilumab leads to no or low disease activity in most moderate-to-severe atopic dermatitis patients: signs, symptoms, and quality of life (poster). British Association of Dermatology Annual Meeting. Edinburgh, Scotland. July 2018.
504. What is the best target for psoriasis: IL-23 vs. IL-17A (invited speaker). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
505. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
506. Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
507. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials (poster). European

- Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
508. Durability of response in patients with chronic plaque psoriasis treated with certolizumab Pegol over 48 Weeks: pooled results from ongoing phase 3, multicentre, randomised, placebo-controlled studies (CIMPASI-1, CIMPASI-2 and CIMPACT) (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 509. Dual neutralisation of IL-17A and IL-17F with bimekizumab improves quality of life in patients with moderate-to-severe plaque psoriasis: results from a phase 2b study and correlation with clinical response (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 510. Maintenance of clinical response in patients with chronic plaque psoriasis switching from etanercept to certolizumab pegol in a phase 3, randomised, controlled study (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 511. Efficacy of certolizumab pegol in psoriasis patients failing to respond to etanercept: results from an ongoing, phase 3, randomised controlled study (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 512. Maintenance of response with up to 3-years of continuous guselkumab treatment: results from the VOYAGE 1 and VOYAGE 2 phase 3 trials (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 513. Defining drug-free remission in psoriasis: results of Delphi exercise (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 514. Ixekizumab provides greater cumulative benefits than other biologic treatments over the first 4 months of treatment (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 515. Ixekizumab provides greater economic value versus other biologic therapies over the first 16 weeks of psoriasis therapy in the USA (poster). European Academy of Dermatology and Venereology annual meeting. Paris, France. September 2018.
 516. Clear skin with no side effects as a modern treatment goal for all your patients with psoriasis (invited speaker). Costal Dermatology Society annual meeting. Monterey, CA. October 2018.
 517. Should TNF blockers be used first line in patients with psoriasis and psoriatic arthritis (invited speaker). Costal Dermatology Society annual meeting. Monterey, CA. October 2018.
 518. Efficacy and safety of risankizumab, an IL-23 Inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase 3 IMMhance trial (invited speaker). National AbbVie webinar training. October 2018.
 519. Clinical insights from the U.S.: why is Tremfya exciting (invited speaker). National Tremfya Launch Meeting. Seoul, Korea. October 2018.
 520. Psoriasis treatment journey: when to start and switch a biologic treatment (invited speaker). National Tremfya Launch Meeting. Seoul, Korea. October 2018.

521. Clear skin with no side effects as a modern treatment goal for all your patients with psoriasis (invited speaker). American Dermatological Association annual meeting. Napa, CA. November 2018.
522. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis (invited speaker). The 48th Annual Meeting of the Japanese Society for Cutaneous Immunology and Allergy. Nara, Japan. November 2018.
523. Advances in targeted therapy for psoriasis and atopic dermatitis: bench-to-bedside success stories (invited speaker). The 48th Annual Meeting of the Japanese Society for Cutaneous Immunology and Allergy. Nara, Japan. November 2018.
524. Defining psoriasis severity: practical considerations (invited speaker). International Psoriasis Council Think Tank. Miami, FL. December 2018.
525. What's new in psoriasis research: focus on translational studies (invited speaker). Maui Derm 2019. Wailea, HI. January 2019.
526. What's new in the atopic dermatitis pipeline (invited speaker). Maui Derm 2019. Wailea, HI. January 2019.
527. Comparison of treatment patterns and healthcare costs between ixekizumab and adalimumab users among psoriasis patients (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
528. Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
529. Experience in patients with a history of malignancy through 3 years of continuous treatment with guselkumab in the VOYAGE 1 and 2 trials (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
530. Pipeline of new therapeutic agents for psoriasis (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
531. Dual neutralization of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe plaque psoriasis: 60-week results from a randomized double-blinded, phase 2b extension study (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
532. Dupixent®: one biologic targeting two inflammatory conditions (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
533. Tildrakizumab efficacy over time stratified by week-28 response levels and by prior biologic use (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
534. Cellular pathways of psoriasis: IL-23, IL-17, and other cytokines (invited speaker). American Academy of Dermatology. Washington, DC, GA. March 2019.
535. Dupilumab adolescent atopic dermatitis clinical study overview (invited speaker). Dallas, Tx. March 2019.
536. Incorporating new information on psoriasis into daily clinical practice (invited speaker). Noah Worcester Dermatological Society 61st Annual Meeting. Rancho Mirage, CA. April 2019.
537. Why complete clearance should be the treatment goal for all your psoriasis patients (invited speaker). Pacific Dermatologic Association Spring Training. Las Vegas, NV. April 2019.
538. Practical tips for using dupilumab for atopic dermatitis patients in your practice (invited speaker). Pacific Dermatologic Association Spring Training. Las Vegas, NV. April 2019.

539. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Live national broadcast. Denver, CO. May 2019.
540. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Live national broadcast. Denver, CO. May 2019.
541. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Live national broadcast. Denver, CO. May 2019.
542. Data overview. Skyrizi® Speaker Training. Denver, CO. May 2019.
543. Development of a psoriasis disease severity score using claims-based data (poster). Society for Investigative Dermatology annual meeting. Chicago, IL. May 2019.
544. Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis (poster). Society for Investigative Dermatology annual meeting. Chicago, IL. May 2019.
545. Targeting IL-23 in psoriasis: a bench-to-bedside success story (part 1: IL-23 biology) (invited speaker). Israel Society for Dermatology and Venereology 40th Annual Meeting. Eilat, Israel. May 2019.
546. Why should I care about clearing skin in my psoriasis patients (invited speaker). Israel Society for Dermatology and Venereology 40th Annual Meeting. Eilat, Israel. May 2019.
547. Targeting IL-23 in psoriasis: a bench-to-bedside success story (part 2: clinical data) (invited speaker). Israel Society for Dermatology and Venereology 40th Annual Meeting. Eilat, Israel. May 2019.
548. Genetic links to disease activity in psoriasis (invited speaker). 24th World Congress of Dermatology. Milan, Italy. June 2019.
549. The cytokine network in psoriasis (invited speaker). 24th World Congress of Dermatology. Milan, Italy. June 2019.
550. Strategies to provide individualized treatment in moderate-to-severe atopic dermatitis (invited speaker). Miami Dermatology Society. Miami, FL. July 2019.
551. Therapeutic update on psoriasis (invited speaker). Washington Dermatology Society annual meeting. Cle Elum, WA. August 2019.
552. Psoriasis and heart disease: we can make a difference (invited speaker). Washington Dermatology Society annual meeting. Cle Elum, WA. August 2019.
553. Adolescent and adult patients with uncontrolled moderate-to-severe atopic dermatitis: visible results now possible (invited speaker). 14th Annual Asthma and Allergy Conference. Girdwood, AL. September 2019.
554. Lymphatic flow blockade amplifies inflammation in imiquimod-induced psoriasis-like skin lesions (poster). 49th Annual ESDR Meeting. Bordeaux, France. September 2019.
555. Efficacy of guselkumab versus secukinumab in patients with moderate-to-severe plaque psoriasis in subgroups defined by previous psoriasis medication history: results from the ECLIPSE study (poster). European Academy of Dermatology and Venereology annual meeting. Madrid, Spain. October 2019.
556. Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, Phase 2b extension study (poster). European Academy of Dermatology and Venereology annual meeting. Madrid, Spain. October 2019.
557. Body mass index and systemic corticosteroid use as indicators of disease burden and their influence on the safety profile of certolizumab pegol across indications (invited speaker). European Academy of Dermatology and Venereology annual meeting. Madrid, Spain. October 2019.

558. KX2-391 ointment 1%, a novel Src phosphorylation and tubulin polymerisation inhibitor, for the treatment of actinic keratosis: results from two pivotal phase III studies (invited speaker). European Academy of Dermatology and Venereology annual meeting. Madrid, Spain. October 2019.
559. Body mass index and systemic corticosteroid use as indicators of disease burden and their influence on the safety profile of certolizumab pegol across indications (poster). American College of Rheumatologists annual meeting. Atlanta, GA. November 2019.
560. Introducing Skyrizi® for adults with moderate to severe plaque psoriasis (invited speaker). Fall Clinical Dermatology Conference. Las Vegas, NV. October 2019.
561. Treatment decisions in psoriasis: what does the patient need to know and shared decision-making (invited speaker). 20th Annual Las Vegas Dermatology Seminar. Las Vegas, NV. November 2019.

Local/Regional/State Presentations (all as invited speaker):

1. Is Kaposi's sarcoma caused by an infectious agent? Miami Dermatologic Society. Miami, FL. March 1996.
2. The role of Langerhans cells in the immunopathogenesis of HIV disease. New York University Department of Dermatology. New York, NY. November 1996.
3. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Walter Reed Medical Center Grand Rounds. Washington, DC. January 1997.
4. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Washington DC Dermatological Society. Bethesda, MD. January 1997.
5. Medical update: HIV/AIDS and the skin. Timothy White Memorial Lecture Series. Whitman-Walker Clinic. Washington, DC. April 1998.
6. Langerhans cells as initial targets for HIV following sexual exposure to virus. NIH Clinical Center Medical Grand Rounds. Bethesda, MD. September 1998.
7. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Center for AIDS Research Grand Rounds. University of Alabama at Birmingham. Birmingham, AL. October 1998.
8. Langerhans cells as initial targets for HIV following sexual exposure to virus. Infectious Disease Grand Rounds. University of Alabama at Birmingham. Birmingham, AL. October 1998.
9. Langerhans cells as initial targets for HIV following sexual exposure to virus. Dermatology Grand Rounds. Northwestern University. Chicago, IL. November 1998.
10. Langerhans cells as initial targets for HIV following sexual exposure to virus. Washington DC Dermatological Society. Bethesda, MD. January 1999.
11. Modeling of early biologic events involved in primary HIV infection. Seminar Series. HIV/AIDS Malignancy Branch, NCI. Bethesda, MD. March 1999.
12. Langerhans cells as initial targets for infection during transmission of HIV. Immunology/Cell Biology Seminar. FCRDC, NCI. Frederick, MD. June 1999.
13. General dermatology issues in the black patient: issues related to dermatology & HIV. Bristol-Myers Squibb Distinguished Faculty Series in HIV. Marion, NC. October 1999.
14. General dermatology issues in the black patient: issues related to dermatology & HIV. Bristol-Myers Squibb Distinguished Faculty Series in HIV. Raleigh, NC. October 1999.
15. The role of dendritic cells in preferential sexual transmission of R5 (macrophage-tropic) HIV. Division of Viral Products Seminar. FDA. Bethesda, MD. October 1999.
16. Langerhans cells as initial targets for HIV following sexual exposure to virus. HIV/AIDS Interest Group Monthly Meeting. University of Texas at Southwestern. Dallas, TX. November 1999.
17. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Dermatology Grand Rounds. University of Texas at Southwestern. Dallas, TX. November 1999.
18. Tissue-based transmission model for HIV infection of Langerhans cells. Division of AIDS Seminar. NIAID. Bethesda, MD. December 1999.
19. Langerhans cells as initial targets for virus during sexual transmission of HIV. Weekly Research Conference. New York Blood Center. New York, NY. February 2000.
20. HIV update. Bristol-Myers Squibb Distinguished Faculty Series in HIV. Columbia, SC. March 2000.
21. Langerhans cells as initial targets for HIV following sexual exposure to virus. Seminars

- in Experimental Pathology. State University of New York Health Science Center at Brooklyn. New York, NY. June 2000.
22. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Grand Rounds in Dermatology. State University of New York Health Science Center at Brooklyn. New York, NY. June 2000.
 23. Skin disease in HIV-infected African-Americans. Bristol-Myers Squibb Distinguished Faculty Series in HIV. Atlanta, GA. August 2000.
 24. The biology and virology of KSHV and how it may cause KS. Duhring Lecture in Dermatology. University of Pennsylvania. Philadelphia, PA. September 2000.
 25. Phenotype and function of HIV-infected dendritic cells. Lecture Series. Division of Retrovirology. Walter Reed Army Institute of Retrovirology. Rockville, MD. September 2000.
 26. The biology and virology of KSHV and how it may cause KS. Grand Rounds in Dermatology. Henry Ford Hospital. Detroit, MI. December 2000.
 27. Randomized double-blind placebo-controlled trial using recombinant human interleukin-10 for patients with moderate-to-severe psoriasis. Washington DC Dermatological Society. Bethesda, MD. January 2001.
 28. HIV-infected dendritic cells impair T cell function: reversal of defects by soluble CD4, but not by anti-retroviral drugs. Translational Research Special Seminar Series. Frederick, MD. May 2001.
 29. Chemically modifies RANTES analogues block CCR5-mediated HIV infection of Langerhans cells within epithelial tissue explants. NIH Symposium on Chemokines in Immunity and Disease. Bethesda, MD. May 2001.
 30. How KSHV may cause KS. Resident Lecture Series. Stanford University. Palo Alto, CA. June 2001.
 31. HIV-infected dendritic cells impair T cell function: reversal of defects by soluble CD4, but not by anti-retroviral drugs. Immunology Lecture Series. Istituto Dermopatico dell'Immacolata. Rome, Italy. September 2001.
 32. How KSHV may cause KS. Immunology Lecture Series. Istituto Dermopatico dell'Immacolata. Rome, Italy. September 2001.
 33. How KSHV may cause KS. Medicine Grand Rounds. VA Hospital. Washington, D.C. October 2001.
 34. The Role of Langerhans Cells in Sexual Transmission of HIV. Dermatology Grand Rounds. Duke University. Durham, NC. December 2001.
 35. Kaposi's Sarcoma-Associated Herpesvirus. Dermatology Grand Rounds. Duke University. Durham, NC. December 2001.
 36. Pityriasis rosea is associated with reactivation of both human herpesvirus-7 and human herpesvirus-6. NIH Clinical Center Medical Grand Rounds. Bethesda, MD. January 2002.
 37. Langerhans cells as initial targets for HIV. NIH Immunology Faculty Lecture Series. Bethesda, MD. April 2002.
 38. Langerhans cells as initial targets for HIV. NIAID Research Lecture Series. Bethesda, MD. April 2002.
 39. Interactions between dendritic cells and HIV. Infectious Disease Grand Rounds. University of Pittsburgh. Pittsburgh, PA. June 2002.
 40. How KSHV may cause KS. Oncology Grand Rounds. University of South Dakota.

- Sioux Falls, SD. October 2002.
41. Cutaneous manifestations of HIV disease. Infectious Disease Grand Rounds. University of South Dakota. Sioux Falls, SD. October 2002.
 42. Pathogenesis of Kaposi's sarcoma. Dermatology Clinical Grand Rounds. Yale University. New Haven, CT. November 2002.
 43. Langerhans cells as targets for HIV. Dermatology Scientific Grand Rounds. Yale University. New Haven, CT. November 2002.
 44. Update on skin diseases associated with human herpesvirus 6, 7, and 8 infection. Harry M. Robinson, Jr., M.D. Memorial Lectureship. University of Maryland School of Medicine. Baltimore, MD. May 2003.
 45. Langerhans cells as targets for HIV. Dermatology Grand Rounds. Oregon Health & Science University. Portland, OR. September 2003.
 46. The role of KSHV in the pathogenesis of KS. Dermatology Grand Rounds. Albert Einstein College of Medicine of Yeshiva University. Bronx, NY. October 2003.
 47. Dermatology perspective on HIV: what it was, what it became, where it may go. HIV/Dermatology Teaching Day. Wilson Memorial Regional Center. Johnson City, NY. November 2003.
 48. Cutaneous manifestations of HIV disease. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2004.
 49. Lymphatic dysfunction in transgenic mice expressing KSHV *k-cyclin* under the control of the *VEGFR-3* promoter. OHSU Cancer Institute 9th Annual Scientific Retreat. Timberline Lodge, OR. July 2004.
 50. Pathogenesis of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2004.
 51. Langerhans cells as targets for HIV. Dermatology Lecture Series. University of Washington. Seattle, WA. September 2004.
 52. Immunology of the skin. Lecture to 2nd year medical students. University of Washington. Seattle, WA. September 2004.
 53. How KSHV may cause KS. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2004.
 54. Mechanisms of action for new biologic therapies for psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2004.
 55. The many faces of flow cytometry. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2004.
 56. Infections and infestations of the skin. Lecture Series for Physician Assistants. Oregon Health & Science University. Portland, OR. December 2004.
 57. Langerhans cell biology and pathology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. December 2004.
 58. Solving the enigmas of Kaposi's sarcoma. Oregon Dermatology Society monthly meeting. Portland, OR. January 2005.
 59. Solving the enigmas of Kaposi's sarcoma. Seattle Dermatology Society monthly meeting. Seattle, WA. January 2005.
 60. Unusual dermatologic cases I. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2005.
 61. Viral carcinogenesis. Graduate school course (Cancer Biology, Cell 616). Oregon Health & Science University. Portland, OR. April 2005.

62. Langerhans cells and HIV infection. Operative Care Division Meeting. VA Medical Center. Portland, OR. May 2005.
63. Langerhans cells and HIV infection. MD, PhD Seminar Series. Oregon Health & Science University. Portland, OR. May 2005.
64. Unusual dermatologic cases II. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2005.
65. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2005.
66. Introduction to immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2005.
67. Immunology of psoriasis and how the biologics work. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2005.
68. Infections and infestations. Dermatology for Primary Care Conference. Portland, OR. September 2005.
69. Infections and infestations. Northwest Oregon Dermatology Nurses' Association annual meeting. Kah-Nee-Ta, OR. October 2005.
70. Infections and infestations. Lecture Series for Physician Assistants. Oregon Health & Science University. Portland, OR. December 2005.
71. Infections and infestations. 37th Annual Family Medicine Review. Portland, OR. February 2006.
72. Psoriasis: key cytokines. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2006.
73. Psoriasis as a T IL-17 autoimmune inflammatory skin disease. Dermatology Lecture Series. University of Miami. Miami, FL. March 2006.
74. Pathogenesis of psoriasis. Rheumatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2006.
75. How HIV interacts with Langerhans cells. Center for AIDS Research. University of Washington. Seattle, WA. April 2006.
76. HIV skin disease - current issues. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. April 2006.
77. New advances in the treatment of psoriatic arthritis. Oregon Dermatology Nurses' Association, Portland, OR. May 2006
78. A biological approach to the management of psoriatic arthritis: treating the complete disease. Redwood City, CA. May 2006.
79. A decade of experience with TNF- α inhibitors & a review of the psoriatic arthritis data. Beverly Hills, CA. May 2006.
80. Current and future biologic treatments for psoriasis. Oregon Society of Dermatology Associates. Portland, OR. May 2006.
81. Langerhans cell and dendritic cell biology in skin. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. June 2006.
82. Cutaneous T cell immunity. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. June 2006.
83. Skin-associated autoimmunity. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. June 2006.
84. Introduction to morphology. Dermatology Lecture Series. Oregon Health & Science

- University. Portland, OR. July 2006.
85. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2006.
 86. Role of IL-23 in the pathogenesis of psoriasis. Dermatology Grand Rounds. UCLA Medical School, Los Angeles, CA. September 2006.
 87. Introduction to immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2006.
 88. Psoriasis. Dermatology for Primary Care Conference. Portland, OR. October 2006.
 89. Recent updates in the treatment of psoriasis. Portland, OR. November 2006.
 90. Recent updates in the treatment of psoriasis. Boise, ID. November 2006.
 91. Role of IL-23 in the pathogenesis of psoriasis. Dermatology Grand Rounds. University of Minnesota Medical School. Minneapolis, MN. November 2006.
 92. Infections and infestations. Lecture Series for Physician Assistants. Oregon Health & Science University. Portland, OR. November 2006.
 93. Emerging data on biologics in psoriasis. Oregon Society of Health System Pharmacists. Portland, OR. November 2006.
 94. HIV disease - update for the dermatologist. Dermatology Grand Rounds. University of Illinois at Chicago. Chicago, IL. November 2006
 95. Recent updates in the treatment of psoriasis. Sacramento, CA. December 2006.
 96. Optimizing therapeutic outcomes with TNF antagonists in the treatment of psoriatic disease. Silverdale, WA. January 2007.
 97. Viruses I. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. February 2007.
 98. Viruses II. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2007.
 99. Psoriasis, psoriatic arthritis & other health conditions. Psoriasis: more than skin deep (National Psoriasis Foundation program). March 2007.
 100. Practical issues involved in using systemic therapy for patients with psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2007.
 101. Improving quality of life in psoriasis with TNF blockers. Eugene, OR. March 2007.
 102. Viral carcinogenesis. Graduate school course (Cancer Biology, Cell 616). Oregon Health & Science University. Portland, OR. April 2007.
 103. IL-23 and psoriasis. Oregon Health & Science University Department of Dermatology 95th Anniversary Educational Celebration in conjunction with the Walter C. Lobitz, Jr., M.D. Visiting Professorship. Portland, OR. April 2007.
 104. IL-23 and psoriasis. Clinical Scholars Visiting Professor. Rockefeller University. New York, NY. May 2007.
 105. Recent updates in the treatment of psoriasis: a case-based approach. Eugene, OR. May 2007.
 106. Dermatology roundtables: practical approaches to solving psoriasis challenges. Portland, OR. May 2007.
 107. Unusual dermatologic cases III. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. May 2007.
 108. Dermspeak - saying and writing accurately and precisely what we see. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2007.

109. Zeroing in on the cause of psoriasis. Oregon Dermatology Society annual meeting. Sunriver, OR. July 2007.
110. Highlights from Society of Investigative Dermatology annual meeting. Oregon Dermatology Society Annual Meeting. Sunriver, OR. July 2007.
111. Basics of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2007.
112. Pityriasis rosea. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2007.
113. State of the art of biologics for psoriasis: today and tomorrow. California Society of Dermatology & Dermatologic Surgery annual meeting. Monterey, CA. September 2007.
114. Immune mediated inflammatory disorders and biologic therapy: clinical considerations for multiple specialties. Houston, TX. September 2007.
115. HIV and skin disease. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2007.
116. Practical use of biologics. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. November 2007.
117. Role of IL-23 and Th17 cells in psoriasis pathogenesis. Dermatology Grand Rounds. University of California at San Diego. San Diego, CA. November 2007.
118. Recent updates in the treatment of psoriasis: a case-based approach. San Diego, CA. November 2007.
119. Unusual dermatologic cases IV. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. December 2007.
120. Diagnosis and management of psoriatic arthritis. Portland, OR. December 2007.
121. Pathogenesis and contemporary treatment of psoriasis. Medicine Grand Rounds. St. Vincent Medical Center. Portland, OR. January 2008.
122. Immunodermatology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2008.
123. Role of IL-23/Th17 cell inflammatory pathway in the pathogenesis of psoriasis. Department of Molecular Microbiology & Immunology annual retreat. Oregon Health & Science University. Portland, OR. March 2008.
124. Advances in the treatment of psoriatic diseases. Portland, OR. March 2008.
125. Burden of psoriatic diseases. Portland, OR. March 2008.
126. Immune mediated inflammatory disorders and biologic therapy: clinical considerations for multiple specialties. San Francisco, CA. April 2008.
127. Biologics. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. April 2008.
128. Common skin diseases. Primary care conference. VA Medical Center. Portland, OR. April 2008.
129. Management of a patient on biologic therapy: a physician nurse interaction. Newport Beach, CA. April 2008.
130. Papulosquamous diseases. Medical student lecture series. Oregon Health & Science University. Portland, OR. April 2008.
131. Recent updates in the treatment of psoriasis: a case-based approach. Oklahoma City, OK. April 2008.
132. The role of IL-23 in the pathogenesis of psoriasis. Dermatology Grand Rounds. University of Oklahoma Health Services University. Oklahoma City, OK. May 2008.

133. A case-based approach to managing psoriasis and psoriatic arthritis in patients with comorbidities. Portland, OR. May 2008.
134. The role of IL-23 in the pathogenesis of psoriasis. Dermatology Grand Rounds. Nara University. Nara, Japan. May 2008.
135. The role of IL-23 in the pathogenesis of psoriasis. Dermatology Grand Rounds. University of Tokyo. Tokyo, Japan. May 2008.
136. Unusual dermatologic cases V. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. May 2008.
137. Langerhans cell and dendritic cell biology in skin. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. May 2008.
138. Psoriasis as a Th17 mediated disease. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. June 2008.
139. Skin-associated autoimmunity. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. June 2008.
140. IL-23 as a master cytokine in psoriasis. John R. Person Lecture in Dermatology. University of Massachusetts. Worcester, MA. June 2008.
141. Co-morbidities, pathogenesis, and treatment of psoriasis. Grand Rounds. Department of Medicine. University of Massachusetts. Worcester, MA. June 2008.
142. Mycobacteria. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2008.
143. Dermspeak - saying and writing accurately and precisely what we see. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2008.
144. IL-23 as a master cytokine in psoriasis. Dermatology Grand Rounds. University of Rochester. Rochester, NY. July 2008.
145. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2008.
146. IL-23 as a master cytokine in psoriasis. Duhring Lecture in Dermatology. University of Pennsylvania. Philadelphia, PA. September 2008.
147. Targeting IL-23: the hottest new wave in treatment of psoriasis. Robert Pommerening Lecture in Dermatology. University of Washington. Seattle, WA. October 2008.
148. IL-23 as a critical target for future psoriasis therapy. Dermatology Grand Rounds. University of Utah. Salt Lake City, UT. October 2008.
149. Identifying and quantifying Th17 cells in psoriasis. Dermatology Basic Science Lecture. University of Utah. Salt Lake City, UT. October 2008.
150. Clinical and therapeutic update on psoriasis. Oregon Society of Health-Systems Pharmacists annual meeting. Portland, OR. October 2008.
151. HIV and skin disease. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2008.
152. Immunology for the dermatology nurse. Northwest Oregon Dermatology Nurses' Association annual meeting. McMinnville, OR. November 2008.
153. Psoriasis: cutting edge advances for an ancient disease. Marquam Hill Lecture Series. Oregon Health & Science University. Portland, OR. November 2008.
154. Imatinib for fibrosing disorders. Translational Medicine Lecture Series. Oregon Health & Science University. Portland, OR. December 2008.

155. Immunodermatology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2009.
156. Biologics. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. April 2009.
157. Emerging pathways in the treatment of plaque psoriasis. Amgen lecture series. Thousand Oaks, CA. April 2009.
158. Papulosquamous diseases. Medical student lecture series. Oregon Health & Science University. Portland, OR. April 2009.
159. Skin cancer. Graduate school course (Cancer Biology, Cell 616). Oregon Health & Science University. Portland, OR. May 2009.
160. Mycobacterial infections. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2009.
161. Dermspeak - saying and writing accurately and precisely what we see. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2009.
162. IL-23, Th17 cells, and psoriasis. Amgen lecture series. Seattle, WA. July 2009.
163. Introduction to immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2009.
164. Psoriasis: more than skin deep. National Psoriasis Foundation educational outreach program. Portland, OR. August 2009.
165. Ustekinumab and briakinumab. Pacific Dermatologic Association annual meeting. Portland, OR. August 2009.
166. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2009.
167. Papulosquamous diseases. Physician Assistants course (Clinical Medicine I, PAST 512). Oregon Health & Science University. Portland, OR. September 2009.
168. Psoriasis. Primary Care Conference. Portland, OR. September 2009.
169. *Candida albicans* as a trigger for psoriasis: new data for an old idea. Maria Turner Retirement Symposium. Bethesda, MD. October 2009.
170. IL-23, Th17 cells, and psoriasis. Rheumatology Grand Rounds. Oregon Health & Science University. Portland, OR. December 2009.
171. Practical aspects of incorporating ustekinumab into your everyday practice. Oregon Dermatology Society monthly meeting. Portland, OR. December 2009.
172. HIV and skin disease. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. December 2009.
173. Papulosquamous diseases. Medical student lecture series. Oregon Health & Science University. Portland, OR. March 2010.
174. Dermatology clinical unknowns. Medical student lecture series. Oregon Health & Science University. Portland, OR. April 2010.
175. Langerhans cell/dendritic cell biology in skin. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. May 2010.
176. Cutaneous T cell immunity. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. May 2010.
177. Psoriasis as a Th17-mediated disease. Graduate school course (Advanced Immunology, MBIM 612). Oregon Health & Science University. Portland, OR. May 2010.

178. Immunology case studies: IgE-mediated allergy. Medical student lecture series. Oregon Health & Science University. Portland, OR. May 2010.
179. Psoriasis. VISN20 Teledermatology Summer Conference. Seattle, WA. June 2010.
180. Introduction to morphology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2010.
181. Role of IL-23 and Th17 cells in the pathogenesis of psoriasis. Pacific Northwest Dermatological 77th Annual Scientific Conference. Vancouver, WA. July 2010.
182. Psoriasis: more than skin deep. National Psoriasis Foundation. Vancouver, WA. July 2010.
183. Introduction to immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2010.
184. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2010.
185. Role of IL-23 and Th17 cells in the pathogenesis of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2010.
186. Systemic therapy for psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2010.
187. Papulosquamous diseases. Physician Assistants course (Clinical Medicine I, PAST 512). Oregon Health & Science University. Portland, OR. September 2010.
188. Common skin diseases in the primary care office. 6th Annual Dermatology for Primary Care Update. Portland, OR. September 2010.
189. Role of IL-23 and Th17 cells in skin infection. Dermatology Grand Rounds. Case Western Reserve University. Cleveland, OH. September 2010.
190. Immunopathogenesis of psoriasis. Dermatology Grand Rounds. University of Florida. Gainesville, FL. October 2010.
191. More than skin deep: essential elements of the skin exam for non-dermatologists. Masters of Physical Diagnosis: The Art of the Physical Exam. Kaiser Permanente CME course. Portland, OR. October 2010.
192. The art of the skin exam. OHSU Dermatology Interest Group workshop. Portland, OR. October 2010.
193. Role of IL-23 and Th17 cells in skin infections and psoriasis. Boehringer Ingelheim Immunology Lecture Series. Ridgefield, CT. November 2010.
194. Common skin diseases in the primary care office. Internal Medicine Lecture Series. Oregon Health & Science University. Portland, OR. December 2010.
195. Getting into dermatology residency. OHSU Dermatology Interest Group workshop. Portland, OR. December 2010.
196. Psoriasis pathogenesis and the psoriasis pipeline. OHSU presentation to Advinus. Portland, OR. January 2011.
197. Common skin diseases in the primary care office. Family Practice Lecture Series. Oregon Health & Science University. Portland, OR. February 2011.
198. Psoriasis. Rheumatology Lecture Series. Oregon Health & Science University. Portland, OR. February 2011.
199. Papulosquamous diseases. Medical student lecture series. Oregon Health & Science University. Portland, OR. April 2011.
200. Skin cancer. Graduate school course (Cancer Biology, Cell 616). Oregon Health & Science University. Portland, OR. May 2011.

201. Unusual dermatologic cases VI. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2011.
202. Unusual dermatologic cases VII. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2011.
203. Introduction to morphology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2011.
204. Introduction to immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2011.
205. Clinical features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2011.
206. Unusual dermatologic cases VIII. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2011.
207. Psoriasis. 7th Annual Dermatology for Primary Care Update. Portland, OR. September 2011.
208. Unusual dermatologic cases IX. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2011.
209. Psoriasis and the development of biosimilars (invited speaker and emcee). Oregon Biomedicine Roundtable on Biosimilars and Biologics: An Interactive Discussion about Innovation, Access and Safety. Portland, OR. October 2011.
210. Unusual dermatologic cases X. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. February 2011.
211. The psoriasis pipeline. Oregon Dermatology Society monthly meeting. Medford, OR. March 2012.
212. Modern systemic management of psoriasis. Oregon Dermatology Society monthly meeting. Medford, OR. March 2012.
213. Pros and cons of clinical trials for patients with psoriasis. National Psoriasis Foundation. Portland, OR. March 2012.
214. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Boone, NC. March 2012.
215. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Tacoma, WA. March 2012.
216. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Green Bay, WI. April 2012.
217. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Milwaukee, WI. April 2012.
218. The psoriasis pipeline. Dermatology Grand Rounds. Medical College of Wisconsin Grand Rounds. Milwaukee, WI. April 2012.
219. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Dodgeville, WI. April 2012.
220. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Madison, WI. April 2012.
221. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. San Francisco, CA. April 2012.
222. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Bend, OR. May 2012.
223. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis.

- Palo Alto, CA. June 2012.
224. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Daytona, FL. June 2012.
 225. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Anchorage, AK. July 2012.
 226. Introduction to immunodermatology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2012.
 227. Dermspeak. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2012.
 228. General features of psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2012.
 229. Cardiovascular effects of biologics. Pacific Dermatologic Association annual meeting. Huntington Beach, CA. August 2012.
 230. Unusual dermatologic cases XI. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. September 2011.
 231. Safety update: patient follow-up through 5 years in clinical trials. Portland, OR. October 2012.
 232. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. San Francisco, CA. October 2012.
 233. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Kansas City, MO. November 2012.
 234. Psoriasis: what's new on the horizon. Portland, OR. November 2012.
 235. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Atlanta, GA. November 2012.
 236. Biologics. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. November 2012.
 237. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Ft. Lauderdale, FL. November 2012.
 238. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Eugene, OR. February 2013.
 239. Immunology underlying the psoriasis pipeline. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2013.
 240. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. St. Louis, MO. March 2013.
 241. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Kansas City, MO. March 2013.
 242. The psoriasis pipeline. Lilly Autoimmune Advisory Board annual meeting. Dallas, TX. March 2013.
 243. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Racine, WI. April 2013.
 244. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Milwaukee, WI. April 2013.
 245. Clinical exchange: dynamic discussions on Stelara for moderate to severe psoriasis. Seattle, WA. April 2013.
 246. Differentiation of ixekizumab in the future psoriasis marketplace. Eli Lilly Lecture. Indianapolis, IN. May 2013.

247. Quality reporting business opportunity assessment. Capstone presentation to Apprise Health Insights. Lake Oswego, OR. June 2013.
248. Structure and function of skin. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. June 2013.
249. Correctly describing skin lesions. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2013.
250. Basic immunodermatology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2013.
251. Psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2013.
252. Management of complex cases of psoriasis. Oregon Dermatology Society annual meeting. Sunriver, OR. August 2013.
253. Off-label uses of biologics. Oregon Dermatology Society annual meeting. Sunriver, OR. August 2013.
254. 21st century management of psoriasis. Intermountain Dermatology Society annual meeting. Sun Valley, ID. September 2013.
255. Management of complex medical dermatology cases. Intermountain Dermatology Society annual meeting. Sun Valley, ID. September 2013.
256. Biologics for psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2013.
257. Psoriasis in the 21st century: more than a skin disease and more you can do it about it. Portland, OR. October 2103.
258. Viruses. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. December 2013.
259. Cutaneous immunology: understanding the basis for targeted therapy in dermatology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2014.
260. Psoriasis: more than skin deep. National Psoriasis Foundation. Portland, OR. June 2014.
261. Update on co-morbidities and biologic treatment options for psoriasis. Grand Rounds. University of California. Irvine, CA. July 2014.
262. 21st century care of psoriasis. Northwest Oregon Chapter of the Dermatology Nurses' Association annual meeting. Portland, OR. October 2014.
263. Update on co-morbidities and biologic treatment options for psoriasis. Grand Rounds. University of Arizona. Tucson, AZ. November 2014.
264. Update on co-morbidities and biologic treatment options for psoriasis. Grand Rounds. Community Memorial Hospital. Ventura, CA. November 2014.
265. Gevokizumab for pyoderma gangrenosum. Columbia Wound Care Consortium. Portland, OR. January 2015.
266. Relevance of brodalumab phase 3 data for the future management of psoriasis. Thousand Oaks, CA. February 2015.
267. Updates from the AAD annual meeting. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2015.
268. Immunology 101. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2015.

269. Dupilumab: molecule background and clinical experience. Regeneron Advisory Board. New York, NY. July 2015.
270. From molecules, to new biologic therapies, to patient outcomes: how a new understanding of psoriasis biology is catalyzing a novel approach to a complex disease. 11th Annual Coastal Dermatology Symposium. Napa, CA. September 2015.
271. Psoriasis: practical considerations for choosing the best therapies. Oregon Society of Dermatology Associates annual meeting. Portland, OR. October 2015.
272. Psoriasis pathogenesis as it relates to new therapeutic agents and clinical practice. Dermatovenerology Clinic lecture series. University of Ljubljana. Ljubljana, Slovenia. November 2015.
273. How advances in psoriasis immunology translate into better biologic therapies. University of Miami Department of Dermatology and Cutaneous Surgery 60th Anniversary Meeting. Miami, FL. January 2016.
274. Psoriasis and psoriatic arthritis: from a dermatologist's perspective. UCB Training Meeting. Portland, OR. February 2016.
275. More than skin deep: hot topics in psoriatic disease research. Portland, OR. May 2016.
276. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Portland, OR. June 2016.
277. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Seattle, WA. June 2016.
278. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Salt Lake City, UT. October 2016.
279. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Eugene, OR. October 2016.
280. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Milwaukee, WI. January 2017.
281. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Denver, CO. January 2017.
282. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Honolulu, HI. January 2017.
283. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Bend, OR. February 2017.
284. Biologics for psoriasis. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. March 2017.
285. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Tigard, OR. April 2017.
286. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Palo Alto, CA. January 2017.
287. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Portland, OR. April 2017.
288. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Reston, VA. May 2017.
289. Introducing a new IL-17A inhibitor for the treatment of adult patients with moderate to severe plaque psoriasis. Portland, OR. May 2017.
290. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Fresno, CA. May 2017.

291. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Albany, OR. June 2017.
292. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Lafayette, CA. June 2017.
293. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. San Jose, CA. June 2017.
294. Update on biologics for psoriasis. Academy of Managed Care Pharmacy regional meeting. Seattle, WA. June 2017.
295. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Las Vegas, NV. June 2017.
296. Basic science of psoriasis. Psoriasis Boot Camp. George Washington University. Washington DC. July 2017.
297. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Bend, OR. August 2017.
298. Clinical insights on Taltz. Portland, OR. August 2017.
299. Basic cutaneous immunology. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. August 2017.
300. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Bellevue, WA. August 2017.
301. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Santa Rosa, CA. September 2017.
302. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Seattle, WA. October 2017.
303. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Tigard, OR. October 2017.
304. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. San Luis Obispo, CA. October 2017.
305. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Eugene, OR. October 2017.
306. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Las Vegas, NV. October 2017.
307. Atopic dermatitis pipeline. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. October 2017.
308. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Salem, OR. November 2017.
309. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Baltimore, MD. November 2017.
310. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Palo Alto, CA. November 2017.
311. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Redding, CA. November 2017.
312. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Portland, OR. November 2017.
313. Cardiovascular disease and psoriasis: what you need to know and what you should tell your patients. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. December 2017.

314. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Fresno, CA. January 2018.
315. A look at Taltz® in psoriatic arthritis. National Webinar. January 2018.
316. A look at Taltz® in psoriatic arthritis. National Webinar. January 2018.
317. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Vancouver, WA. January 2018.
318. A look at Taltz® in psoriatic arthritis. National Webinar. January 2018.
319. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Wailea, HI. January 2018.
320. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. Salem, OR. February 2018.
321. A closer look at Taltz®. Portland, OR. February 2018.
322. A look at Taltz® in psoriatic arthritis. National Webinar. February 2018.
323. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Olympia, WA. February 2018.
324. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. National Webinar. February 2018.
325. A look at Taltz® in psoriatic arthritis. National Webinar. February 2018.
326. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. National Webinar. February 2018.
327. A closer look at Taltz®. Bend, OR. February 2018.
328. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. National Webinar. February 2018.
329. Tremfya®: introducing the first-in-class novel biologic that selectively blocks interleukin-23. National Webinar. February 2018.
330. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Salem, OR. March 2018.
331. Intersecting careers in medicine, science, and business. University of Maryland Baltimore Campus Career Seminar. Baltimore, MD. March 2018.
332. A closer look at Taltz®. San Carlos, CA. March 2018.
333. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Yountville, CA. April 2018.
334. Dupixent® (dupilumab): the first biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Oakland, CA. April 2018.
335. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Detroit, MI. April 2018.
336. A closer look at Taltz®. Woodside, CA. May 2018.
337. A look at Taltz® in genital psoriasis. National Webinar. May 2018.
338. A closer look at Taltz®. Tigard, OR. May 2018.
339. Dupilumab (Dupixent®): a bench-to-bedside success story for atopic dermatitis. Nara University. Nara, Japan. May 2018.
340. Dupilumab (Dupixent®): a bench-to-bedside success story for atopic dermatitis. Chiba University. Chiba, Japan. May 2018.
341. Dupilumab (Dupixent®): a bench-to-bedside success story for atopic dermatitis. Yamanashi University. Kofu City, Japan. May 2018.
342. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis. Catholic University of Korea. Seoul, South Korea. May 2018.

343. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis. Asan Medical Center. Seoul, South Korea. May 2018.
344. Clinical overview of dupilumab (Dupixent®), a novel biologic therapy for atopic dermatitis. Ajou University Hospital. Seoul, South Korea. May 2018.
345. Taltz: perspectives from dual specialties. Spokane, WA. May 2018.
346. Tremfya®: a selective IL-23 inhibitor with pivotal studies vs adalimumab. Richland, WA. June 2018.
347. Tremfya®: a selective IL-23 inhibitor with pivotal studies vs adalimumab. National Webinar. June 2018.
348. Tremfya®: a selective IL-23 inhibitor with pivotal studies vs adalimumab. Las Vegas, NV. June 2018.
349. Tremfya®: a selective IL-23 inhibitor with pivotal studies vs adalimumab. National Webinar. July 2018.
350. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. National Webinar. July 2018.
351. Taltz: perspectives from dual specialties. Salt Lake City, UT. July 2018.
352. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Boston, MA. August 2018.
353. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Nashua, NH. August 2018.
354. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. National Webinar. August 2018.
355. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. National Webinar. September 2018.
356. Tremfya®: a selective IL-23 inhibitor with pivotal studies vs adalimumab. National Webinar. September 2018.
357. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Saratoga, CA. October 2018.
358. Dupixent® (dupilumab): the first and only biologic for adults with uncontrolled moderate-to-severe atopic dermatitis. Seattle, WA. October 2018.
359. Update on pathogenesis and treatment of atopic dermatitis. Division of Allergy and Infectious Diseases Grand Rounds. University of Washington. Seattle, WA. October 2018.
360. Unknowns. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. January 2019.
361. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. National Webinar. January 2019.
362. Unknowns. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. February 2019.
363. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. National Webinar. February 2019.
364. Dupixent®: one biologic targeting two inflammatory conditions. San Francisco, CA. February 2019.
365. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. Reno, NV. March 2019.
366. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. Dayton, OR. March 2019.

367. Dupixent®: one biologic targeting two inflammatory conditions. Portland, OR. March 2019.
368. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. Seattle, WA. March 2019.
369. Tremfya®: a first-line biologic with clinical data vs adalimumab and secukinumab. Olympia, WA. March 2019.
370. Dupixent®: visible results for adolescents (12+ years of age) with uncontrolled moderate-to-severe atopic dermatitis. Portland, OR. April 2019.
371. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Portland, OR. May 2019
372. Dupixent®: adolescent and adult patients with uncontrolled moderate-to-severe atopic dermatitis: visible results now possible. Sacramento, CA. May 2019.
373. Dupixent®: adolescent and adult patients with uncontrolled moderate-to-severe atopic dermatitis: visible results now possible. Salem, OR. May 2019.
374. The future of biologic therapy in dermatology: can we get better? Grand Rounds. Department of Dermatology. Icahn School of Medicine at Mount Sinai. New York, NY. June 2019.
375. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Salem, OR. June 2019.
376. Psoriasis: the basics. Dermatology Lecture Series. Oregon Health & Science University. Portland, OR. July 2019.
377. Psoriasis and heart disease: we can make a difference. Grand Rounds. Department of Dermatology and Cutaneous Surgery. University of Miami. Miami, FL. July 2019.
378. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Miami, FL. July 2019.
379. Practical tips for using dupilumab. Dermatology Lecture Series. Department of Dermatology and Cutaneous Surgery. University of Miami. Miami, FL. July 2019.
380. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Cle Elum, WA. August 2019.
381. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Scottsdale, AZ. August 2019.
382. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Las Vegas, NV. August 2019.
383. Data update on biologic therapy for atopic dermatitis. Oregon Society for Allergy, Asthma, and Immunology Northwest Allergy Forum. Portland, OR. October 2019.
384. The burgeoning therapeutic pipeline for atopic dermatitis. Oregon Society for Allergy, Asthma, and Immunology Northwest Allergy Forum. Portland, OR. October 2019.
385. Introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Portland, OR. October 2019.
386. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Portland, OR. November 2019.
387. What is science? Our Lady of the Lake School. Lake Oswego, OR. November 2019.
388. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Portland, OR. November 2019.
389. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Eugene, OR. November 2019.

390. Clear conversations: introducing Skyrizi® for adults with moderate to severe plaque psoriasis. Portland, OR. December 2019.